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4
Summary
In clinical trials when comparing two treatment groups A and B it is common to
use a composite event E consisting of the union of two or more distinct outcomes
(E = E1 [ E1). For example, in cardiovascular studies it is usual to use a composite
event consisting of Death (E1) and Target Vessel Revascularization (E2).
The advantages and drawbacks of using a composite event have been reported
in several papers. Most of these papers focus the debate on the medical perspec-
tive rather than as a statistical problem. Based on Go´mez and Lagakos (2011) paper
we consider the asymptotic relative efficiency (ARE) of a logrank test for comparing
treatment groups with respect to a primary endpoint versus the composite endpoint
to decide when it should be better to use a composite endpoint.
We focus this master thesis on the cardiovascular area and more precisely on the
cardiovascular device studies involving coronary stents. As Go´mez and Lagakos
show, the ARE depends basically on the correlation between the times until E1 and E2,
on the hazard ratios and on the probability of occurrence of each endpoint. We have
developed a literature search strategy on Pubmed database studies (randomized clin-
ical trials, data from registries and observational studies) in order to gain knowledge
about the distinct components used in the composite endpoints and to find real life
parameters values used in that kind of studies. Finally, statistical recommendations
to decide whether to expand a study primary endpoint from E1 to the composite of E1
and E2 have been analyzed from the ARE results.
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Chapter 1
General Introduction to Composite
Endpoints
In time-to-event analysis when comparing two treatment groups it is common to use
a composite outcome, sometimes called combined outcomes, consisting of two or
more distinct outcomes. For example, in cardiovascular studies we can construct a
composite endpoint (E) consisting of cardiac death (E1) and stroke (E2). When using
a composite endpoint individuals are followed until the event of interest, E1 or E2,
whichever occurs first.
Literature shows that there has been a great debate about the advantages and
disadvantages about using a composite endpoint, but surprisingly there is very little
discussion about statistical considerations about this issue.
1.1 Main objectives
The principal aim of this thesis is to develop recommendations to decide when it
would be better to use a composite endpoint consisting in adding an extra endpoint
to the primary endpoint in stent coronary clinical trials studies. This guide will be
based on the statistical efficiency as a function of a small number of interpretable
parameters.
In order to achieve this principal objective we have had to undertake many different
tasks, from doing a systematic literature review, to learn how to use the Maple Soft-
ware passing by a deeper understanding of the asymptotic survival theory, and last
but not least, to learn how to use the Latex environment to write this thesis. In what
follows we itemize some of the most important steps done for the achievement of this
work:
1. State of the art on composite issues endpoints. Advantages and disadvantages
of using composite outcomes.
2. Statistical theory needed to compute the relative efficiency of a composite end-
point vesus a primary endpoint.
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3. Literature search on stent coronary clinical trials. Identification of a range of val-
ues for each relevant parameter involved in the computation of the asymptotic
relative efficiency.
4. Adapt Maple computations following the Go´mez and Lagakos’s paper [16] to
the specific set of values for stent cardiovascular clinical trials.
5. Execute the programs and analyze the results.
6. Propose guidelines for the use of composite endpoint in stent cardiovascular
trials.
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Chapter 2
The Composite Endpoint
2.1 Background about Clinical Trials
A clinical trial is a research study designed to provide extensive data that will allow
for statistically valid evaluation of treatment or interventions on a group of individ-
uals [20]. The study compares outcomes (or endpoints) in the group of participants
receiving a new treatment with a comparable control group receiving either the stan-
dard treatment or a placebo (see Figure 2.1). A randomized clinical trial (RCT) is
the optimal experimental method used to determine which of two treatments has the
most favorable outcome. The main reason for using a RCT is to avoid bias in the
allocating of the patients to each treatment and hence to make comparable treatment
groups. A sophisticated allocation that permits removing bias and balancing prog-
nostic factors can be an alternative method but randomization is the only method that
balances both known and unknown factors.
We have two approaches for about clinical trials results: evidence and decision
[8]. The first one is Fisher’s perspective, since we obtain the quantity of information
(evidence) that we have obtained in the test regarding the mean differences. For
example, in a test of mean differences we may obtain a p-value of the statistic equal
to 0.09. On the other hand, in Neyman-Pearson’s perspective, investigators have to
Target  
POPULATION 
Group B 
Allocation 
Group A 
Response 
Sample 
Follow-up 
Response 
Figure 2.1: Global scheme of a Clinical trial.
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decide and make yes/no decisions [27] based on whether or not a p-value obtained
in the test lets us to reject a null hypothesis to the alternative by fixing (a priori) a
boundary for the alpha level. That is, a researcher wants to achieve enough evidence
to confirm that treatment B is more effective than treatment A (or placebo) and in
these cases the power of the test (the probability of rejecting the null hypothesis when
it is false) plays an important role.
It is important how we measure the values of the endpoints, since endpoints that
require subjective judgment are subject to bias [23]. For example, death is easy to
know (yes/not) but x-rays interpretation can be different depending on different doc-
tor’s evaluation. So the validity and reliability of the measure would be imperfect,
making bias about systematic and proportional errors.
Nowadays, clinical trials are used frequently in many areas like oncological and
cardiovascular studies [1, 15].
2.2 Definition of Composite Endpoint and Statistical No-
tation
Composite endpoints are defined as the occurrence of any event from among a given
set of events after a certain period of follow-up [12].
Consider a two-arm randomized study with random assignment either to a con-
trol treatment (X=0) or to an active treatment (X=1). For instance, the control treat-
ment group could be a placebo medicine or standard of care and the active treatment
group corresponds to a new therapy or treatment. We follow patients from random-
ization until the occurrence of one set of clinical outcomes.
For a given clinical trial suppose that you only have two endpoints of interest that
we denote by E1 or primary endpoint and E2 or secondary endpoint. For example,
we could have Cardiovascular Death and Stroke as primary endpoints and Myocardial
Infarction as secondary endpoint.
Individuals in the clinical trial are followed until the event occurs or until the
study ends. The times to E1 and E2 are denoted respectively by T1 and T2 and they are
assumed to be absolutely continuous so ties cannot occur. C represents the time from
randomization to the end of the study and this administrative censoring is the only
noninformative censoring cause.
Define the composite endpoint as E = E1 [ E2 and T = minfT1; T2g as the time
to the occurrence of the earlier element of the composite E1 or E2. Note that T will
be always observed if T < C. That is, with the composite we observe whichever
occurs first of the E1 and E2 and then we always will see T except when we observe
a censoring time before.
On the other hand, observations of endpoints E1 and E2 depend on whether or not
they include a terminating event. For example, we will not always observe T1, the
time to event (Stroke) if E2 includes Death.
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Case 1 
Case 2 
Case 3 
Case 4 
SE PE 
NF 
NF 
NF 
F 
F 
F 
Figure 2.2: Scheme for the 4 possible cases. PE stands for Primary Endpoint, F stands for Fatal event and NF
for Non Fatal Event. The two endpoints could occur in either order.
So, regarding the different combinations of E1 and E2 depending if they include a
terminating event or not we can consider the following four cases (see Figure 2.2):
Case 1: Neither of the two endpoints (E1, E2) includes a terminating event. We
observe Tj (j = 1; 2) (time to event 1 or 2) if Tj occurs before the right-censoring time
C. That is, we observe the time until the E1 if T1 is not censored by C. And the same
happens for T2.
Case 2. The primary event does not include a terminating event while the sec-
ondary event includes a terminating event. Hence, we observe T1 if T1 < minfT2; Cg.
That is we observe T1 if T1 occurs before T2 and C. And we observe T2 if T2 < C . So
T2 will be observed if T2 occurs before the censoring.
Case 3. The primary endpoint includes a terminating event, but the secondary
event does not include a terminating event. Then, we will observe T1 if T1 < C and
T2 if T2 < minfT1; Cg. That is to say, we observe T1 if T1 occurs before the censoring,
and we observe T2 if T2 occurs before T1 and C.
Case 4. Both events (E1, E2) include a terminating event. We observe T1 if T1 <
minfT2; Cg and observe T2 if T2 < minfT1; Cg. That is, we observe T1 if T1 occurs
before T2 and C, and we observe T2 if T2 occurs before T1 and C.
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Note that in Cases 2 and 4 the secondary endpoint includes a terminating event
which is competing with the censoring random variable C in the observation of E1
and the endpoint T1 is right-censored by minfT2; Cg. Thus, in cases 2 and 4 we have
a competing risk situation with dependent censoring on T1. This fact should be taken
into account in the derivations.
The composite endpoint T is right-censored by C in all four cases and the ob-
served outcome will be denoted as U = minfT; Cg.
2.3 Advantages and Disadvantages of Composite End-
points
One advantage of using a composite endpoint is that we can reduce the problem of
multiple comparisons (or multiplicity) to analyze the results [12, 14, 23, 37]. So
if we take many events separately (and so many number of tests) it would require a
stronger level of evidence to avoid spurious positive conclusions and hencewewould
have to modify the initial alpha error (the error of rejecting a null hypothesis when it
is actually true) [13]. Moreover, using a composite endpoint we avoid bias associated
with competing risks [37]. For example, if nonfatal myocardial infarction is the event
of interest, death is a competing risk. So if death rate in the treatment group is higher
than in the control group, the number of patients at risk of suffering myocardial in-
farction in the treatment group will be reduced. Thus, if we focus on the total rate
of myocardial infarction, the estimated treatment effect would be biased suggesting
that the treatment reduces myocardial infarction. But the use of the composite (death
or myocardial infarction) may reveal that there is no overall benefit of treatment [12].
In some trials, studying nonfatal events without including death could bemethod-
ologically invalid [23], since death outcome would censor the rest of outcomes. It is
important because a treatment may decrease the number of non-fatal events only
because mortality is increased. For example, the effect of a composite of non-fatal in-
farctions and stroke can be reduced because a treatment effect increases the mortality.
So with the composite endpoint we have the possibility to add a fatal event in our
primary outcome.
The choice of a primary endpoint in some areas is not the ultimate clinical end-
point of interest, but rather some surrogate believed to be relevant for predicting the
effect of the intervention on the clinical outcome of interest [37]. For example, in HIV
field the pathogenesis is sufficiently understood so that the effect of a drug regimen
on the viral load (CD4) is accepted as being relevant for understanding the contri-
bution of the treatment to AIDS and death from AIDS. This choice is done because
the clinical endpoint of interest may be rare and take many years to occur. So in HIV
studies the composite outcomes used are usually a combination of surrogate markers
(e.g. viral load) and true clinical endpoints (e.g. death or progression to AIDS).
However, there are some disadvantages when using a composite endpoint. When
we create a composite we are analyzing somehow different than when using a single
primary endpoint. So we should be aware of what is actually the medical meaning
of the composite endpoint. Doctors can use a composite endpoint to measure the
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differences of a global measure for drug efficacy defined about a disease process [27,
36, 37] or a complex disease (e.g., the assessment of skeletal-related events in trials
for prevention or treatment of bone metastases [23]), but actually the global effect
of a composite could also be confounding if the elements (events) are quite different
between them due to its heterogeneity [12]. In short, we get greater uncertainly in
interpretation of the composite endpoint results [14]. Moreover, when investigators
report the primary endpoint as a composite it is important to take into account that
we cannot attribute proof of efficacy (or lack) to each individual component of the
composite [14, 12] and components should always be defined as secondary endpoints
analyzing and reporting them separately [14, 34] and if possible classifying them by
levels of clinical importance [12].
When doctors decide to use a composite endpoint they should recognize the rela-
tion of the elements included in the composite. So there are two main characteristics:
relevance and relationship with the objectives and potential effect for each end-
point [14]. First, if we decide to use a composite endpoint, and then to include an-
other endpoint apart from the primary, this extra endpoint should be relevant enough
for the objectives of the study. For example, in a cardiovascular study with cardiac
death as a primary endpoint may not be acceptable to add number of headaches or
another endpoint with less importance to the patients [10] to increase the number of
events. In this case, we could achieve to demonstrate statistical differences but not
a credible and serious report. That is, we could have enough statistical significance
but not clinical importance [27]. So clinical trialists should construct composite end-
points only when components endpoints are of similar patient-importance [14, 11, 26]
[34, 37] and pharmaceutical regulators should have control on that [13]. Secondly, in-
vestigators could be tempted to add an endpoint that will give them high number of
observed events (for example hospitalizations) [14] to increase the efficiency but, if
this endpoint have a lower effect in each treatment they will not be able to reject the
null hypothesis of equality of the treatment effects although the power has increased.
So using of composite endpoint could be disadvantageous when the effect of the ther-
apy on components diverges (different treatment effects) [12, 34] and, when large
variations exist between components, the composite endpoint should be abandoned
[26]. And obviously the clinically more important components of the composite end-
points should at least not be affected negatively [23]. Moreover, when clinician driven
outcomes, such as revascularization or hospitalization are used, these appear gener-
ally to be more amenable to change, presenting further challenges for interpretation
[14].
In cardiovascular device trials involving coronary stents, it is common to take the
rare endpoints of cardiovascular death and myocardial infarction and combine with
a more frequent endpoint. For example, considering cardiovascular death as a pri-
mary endpoint maybe we would not have enough number of events to see statistical
differences. Making a composite of death and hospitalization (whichever occurs the
first) we will probably increase the power but if the hospitalization endpoint is af-
fected similarly by both treatments we will not be able to demonstrate the differences
about the effects even if hospitalization has a lot of occurrences [9]. That is, the weight
of the hospitalization endpoint will balance the effect of the composite endpoint for
both treatments. So investigators could rise to see opposite conclusions than they
estimated at the beginning.
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The following questions should be answered before deciding whether to use a
composite endpoint or not [23]:
 Does the composite endpoint really measure a disease?
 Does the use of a composite endpoint solve a medical problem or is it just for
statistical convenience?
 Are the individual components of the composite endpoint valid, biologically
plausible, and of importance for patients?
 Are the results clear and clinically meaningful? Do they provide a basis for
therapeutic decisions? Does each single endpoint support the overall result?
 Is the statistical analysis adequate?
In summary, we see the existence of a debate about the main advantages and dis-
advantages that one can find in literature, but there is very little discussion about
statistical solutions to decide whether to use a composite endpoint versus an end-
point that belongs to a subset of the components of the composite. Investigators have
to evaluate the value for money and the cost-effectiveness [27] for each combination
to optimize their resources. And the decision of using a composite should be based
on investigators experience and medical framework recommendations but also, as
we will see in this thesis, statistical guidelines should be taken into account.
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Chapter 3
Introduction to the Cardiovascular
Stents
We are focusing this Master Thesis on the cardiovascular area and in particularl in
stent cardiovascular clinical trial studies. We give next a brief definition of stents and
other related concepts.
3.1 Definition of a Coronary Stent
A stent is a tube placed inside a duct or canal to reopen it or keep it open. It may be a
simple tube, usually plastic, or an expandable, usually sprung mesh metal tube (see
Figure 3.1).
Figure 3.1: Picture of a coronary stent.
When a stent is placed into the body, the procedure is called stenting.
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Most stents are made of a metal (bare stents) while other are of plastic mesh-like
material. However, stent grafts (or covered stents) used in larger arteries are made of
fabric which creates a stronger inner lining for the artery. Nowadays there are several
bio-absorbable stents in development and these are the focus of many clinical trials.
These stents are made from a variety of biodegradable polymer materials, such as
organic biopolymers and corrodible metals.
There are different types of stents. An intraluminal coronary artery stent is a small,
self-expanding, metal mesh tube that is placed inside a coronary artery after balloon
angioplasty to prevent the artery from re-closing. A drug-eluting stent (DES) is coated
with a medicine that helps further prevent the arteries from re-closing. Like other
coronary stents, it is left permanently in the artery.
3.2 Why are Stents Used?
Coronary artery disease occurs when cholesterol plaque builds up (atherosclerosis)
in the walls of the arteries to the heart (see Figure 3.2) and then the coronary artery
(an artery feeding the heart muscle) is narrowed by a buildup of fatty deposits called
plaque, and it can reduce the blood flow. If this occurs, chest pain can result and if a
clot blocks the blood flow to part of the heart muscle, a heart attack results.
Figure 3.2: Picture of a blocked artery.
So stents help keep coronary arteries open and reduce the chance of a heart attack.
And when it is necessary to open a narrowed artery, a doctor may do a procedure
called angioplasty.
3.3 Definition of Coronary Angioplasty (PCI)
Coronary Angioplasty, also called percutaneous coronary intervention or PCI, is a
minimally invasive procedure performed to improve blood flow in the body’s arter-
ies and veins and (with or without vascular stenting) is commonly used to treat con-
ditions that involve a narrowing or blockage of arteries or veins throughout the body,
including narrowing of large arteries (aorta and its branches) due to atherosclerosis.
In an angioplasty procedure using image guidance, an inflatable balloonmounted
at the tip of a catheter is inserted through the skin into an artery (see Figure 3.3) and
advanced to the site of an arterial blockage where the balloon is inflated and deflated.
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In this process, the balloon expands the artery wall, increasing blood flow through
the artery. The balloon is then deflated and removed.
Figure 3.3: Picture of an angioplasty procedure.
When a stent is used, it’s collapsed to a small diameter and put over the balloon
catheter (see Figure 3.4). It’s then moved into the area of the blockage. When the
balloon is inflated, the stent expands, locks in place and forms a scaffold. The stent
stays in the artery permanently and holds it open. This improves blood flow to the
heart muscle and relieves symptoms (usually chest pain).
Figure 3.4: Picture of a Stent insertion.
Stenting has become fairly common and the majority of angioplasty procedures are
done using stents.
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3.4 Using Stents. The Benefits versus Risks
Using stents have benefits and also some risks compared to surgical interventions
that we should take into account.
Benefits
 Compared to surgical interventions such as bypass surgery, balloon angioplasty
and stent placement are much less invasive and relatively low-risk and with
low-cost procedures.
 These procedures are performed using local anesthesia. No general anesthetic
is required in the majority of patients.
 No surgical incision is needed. Only a small nick in the skin that does not have
to be stitched closed.
 Patients return to their normal activities shortly after the procedure and they
have much less discomfort, too.
Risks
 Inserting the catheter can lead to injury of the artery. The balloon also poses a
risk of blood clots or tearing the artery.
 When angioplasty is performed alone, blockages can recur, although most of
these arteries can be opened again successfully. This can also occur when a
stent is placed in the artery at the time of the angioplasty.
 Heavy bleeding from the catheter insertion site may require special medication
or a blood transfusion.
 There is a risk of stroke when angioplasty and/or stenting are performed on the
carotid artery.
 Other rare complications include heart attack and sudden cardiac death. More-
over, any procedure where the skin is penetrated carries a risk of infection and
there is a very slight risk of an allergic reaction if contrast material is injected.
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Chapter 4
Statistical Methodology
The following statistical methodology and technical procedures summarize Go´mez
and Lagakos findings developed in ”Statistical Considerations in the Use of a Com-
posite Time-to-Event Endpoint for Comparing Treatment Groups” (2011) [16].
As discussed before, there has been a great debate in the literature concerning the
use of composite endpoints in time-to-events analysis but very little discussion about
statistical considerations to elucidate whether to use a composite endpoint or one of
its components endpoints.
The main goal is therefore to derive guidelines for deciding when it is recom-
mended to expand a primary endpoint from E1 to the composite of E1 and E2 in stent
cardiovascular studies.
We will follow the notation given in section 2.2 and review the main findings in
Go´mez and Lagakos (2011) focusing on the Case 3 situation (see Figure 4.1). In stent
cardiovascular studies the primary endpoint always include cardiovascular death or
death due to any cause, while the secondary endpoint to be added is not in general a
terminating event.
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Case 1 
Case 2 
Case 3 
Case 4 
SE PE 
NF 
NF 
NF 
F 
F 
F 
Figure 4.1: Scheme for the 4 possible cases. PE stands for Primary Endpoint, F stands for Fatal event and NF
for Non Fatal Event. The two endpoints could occur in either order.
Assume that we have two independent samples and a total sample size of n indi-
viduals. The efficiency calculations will be evaluated based on a sequence of contigu-
ous alternatives to the null and based on the following assumptions:
Assumption 1: For a total sample size of n individuals, let n = PrH0fX = 1g denote
the probability under the null of being allocated to group 1.
Assumption 2: End-of-study censoring at time  (without loss of generality we take
 = 1) is the only noninformative censoring cause, that is, PrfC > tg = 1f[0;  ]g(t) =
1f[0; 1]g(t).
Assumption 3: End-of-study censoring is identical across groups, that is, PrfC >
tjX = 0g = PrfC > tjX = 1g = PrfC > tg = 1f[0;  ]g(t). This assumption facilitates
computations and derivations although the general expressions could be analogously
stated without it.
Assumption 4: Treatment groups have proportional hazards. The proportionality
assumption is given by the hazard ratios 
(1)
1 (t)

(0)
1 (t)
= HR1 and

(1)
2 (t)

(0)
2 (t)
= HR2 for all t.
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4.1 Logrank Test for the Primary Endpoint
Recall that T1 is the time to the primary event E1 and that individuals have been
randomized to one of two groups.
When comparing two treatment groups we stablish the null hypothesis
H0 : S
(0)() = S(1)(), or equivalently by: H0 : (0)1 () = (1)1 ()
where S(0)() and S(1)() are the survival functions of T1 for group 0 and 1 respec-
tively, and (0)1 () and (1)1 () represent the hazard functions for each group. It is very
common to use the logrank test statistic Z to test H0.
The logrank test Z under the hypothesis of no treatment difference is asymptot-
ically normally distributed N(0; 1). The large sample behavior of Z when H0 does
not hold is considered for a sequence of alternatives and under these conditions Z is
asymptotically normal with unit variance and mean  given by
 =
p
n
R1
0
log
(1)1 (t)

(0)
1 (t)
	
p(t)[1  p(t)]PrH0fU  tg(0)1 (t)dtqR1
0
p(t)[1  p(t)]PrH0fU  tg(0)1 (t)dt
(4.1)
where n is the total sample size, U is the observed outcome given by U = minfT1; Cg,
p(t) = PrH0fX = 1jU  tg is the null probability that, someone at risk at time t, is
in treatment group 1, PrH0fU  tg is the null probability that someone is still at risk
at time t and PrH0fU  tg(0)1 (t) corresponds to the probability, under the null, of
observing event E1 by time t.
If we denote by T2 the time to the secondary event E2 and by T = minfT1; T2g the
time to the composite endpoint, to test the null hypothesis of no treatment difference
based on T, H0 : 
(0)
 () = (1) ()we use as well the logrank test statistic Z.
Analogously as above, under H0 Z is is asymptotically N(0; 1), and when H0 does
not hold, Z is asymptotically normal with unit variance and mean  given by
 =
p
n
R1
0
log
(1) (t)

(0)
 (t)
	
p(t)[1  p(t)]PrH0fU  tg
(0)
 (t)dtqR1
0
p(t)[1  p(t)](0) (t)PrH0fU  tgdt
; (4.2)
where p(t) = PrH0fX = 1jU  tg is the null probability that, someone at risk at time
t, is in treatment group 1 and PrH0fU  tg is the null probability that someone is still
at risk at time t.
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4.2 The Asymptotic Relative Efficiency (ARE)
We use the asymptotic relative efficiency of Z versus Z to discriminate whether to
use the composite endpoint or the primary endpoint.
Given that both tests Z and Z are asymptotically N(0,1) underH0 andH0 , respec-
tively, and are asymptotically Normal with variance 1 under a sequence of contiguous
alternatives to the null, their asymptotic relative efficiency is given by:
ARE(Z; Z) =



2
; (4.3)
where  and  can be replaced by (4.1) and (4.2).
The rule to decide when will be recommended to use the composite or not will be
as follows:
 When ARE(Z; Z) > 1) the composite endpoint should be used.
 When ARE(Z; Z)  1) the primary endpoint should be used.
Go´mez and Lagakos use a more flexible rule such that the composite endpoint is
always used if ARE(Z; Z) > 1:25, it is never used if ARE(Z; Z) < 1:1, and when-
ever 1:1 < ARE(Z; Z) < 1:25 the benefits of using the composite endpoint over the
primary endpoint on the particular setting are studied based on other grounds.
As it is developed in Go´mez and Lagakos paper, the noncentrality parameter  given
in 4.1 can be expressed as:
 =
p
nn(1  n)
R1
0
log
(1)1 (t)

(0)
1 (t)
	PrH0fUtjX=1gPrH0fUtjX=0g
PrH0fUtg

(0)
1 (t)dtqR1
0
PrH0fUtjX=1gPrH0fUtjX=0g
PrH0fUtg

(0)
1 (t)dt
: (4.4)
and the noncentrality parameter  given in (4.2) becomes equal to
 =
p
nn(1  n)
R1
0
log


(1)
 (t)

(0)
 (t)
	
PrH0 fUtjX=1gPrH0 fUtjX=0g
PrH0 fUtg

(0)
 (t)dtrR1
0
PrH0 fUtjX=1gPrH0 fUtjX=0g
PrH0 fUtg

(0)
 (t)dt
:
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Taking into account that the endpoint T1 is right-censored by C and that the null hy-
pothesis of no effect H0 : 
(0)
1 () = (1)1 () implies the equality of the marginal survival
functions S(0)1 (t) = S
(1)
1 (t), the noncentrality parameter  in 4.4 becomes equal to
 =
p
nn(1  n)
R 1
0
log
(1)1 (t)

(0)
1 (t)
	
f
(0)
1 (t)dtqR 1
0
f
(0)
1 (t)dt:
(4.5)
where f (0)1 (t) is the marginal density function for T1 in group 0.
Following analogous derivations, denoting by f (0) (t) the marginal density func-
tion for T in group 0 and taking into account that underH0 : 
(0)
 () = (1) (), we have
S
(0)
 (t) = S
(1)
 (t), the expression for the noncentrality parameter  becomes
 =
p
nn(1  n)
R 1
0
log


(1)
 (t)

(0)
 (t)
	
f
(0)
 (t)dtqR 1
0
f
(0)
 (t)dt
: (4.6)
Replacing (4.5) and (4.6) in (4.3), the ARE is given by
ARE(Z; Z) =



2
=
R 1
0
log


(1)
 (t)

(0)
 (t)
	
f
(0)
 (t)dt
2
(log HR1)2(
R 1
0
f
(0)
 (t)dt)(
R 1
0
f
(0)
1 (t)dt)
(4.7)
where 
(1)
1 (t)

(0)
1 (t)
has been substituted by the constant hazard ratio, HR1, established in
Assumption 4.
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4.3 The Asymptotic Relative Efficiency as a Function of
Interpretable Parameters
The close study of ARE(Z; Z) reveals that it only depends on:
 The marginal law of T1 (f (0)1 (t))
 The law for T in group 0 (f (0) (t)) and the hazard functions (0) (t) and (1) (t)
 The hazard ratio for the primary endpoint (HR1)
The law for T for each group can be derived from the bivariate distribution of
(T1; T2). The joint law of (T1; T2) is specified as a function of the marginal densities
f
(0)
1 (t1) and f
(0)
2 (t2) and an association parameter  via Frank’s copula model.
If we assume equal association parameter  for groups 0 and 1, the joint density
and bivariate survival functions for (T1; T2) in group j (j = 0; 1) are given by:
f
(j)
(1;2)(t1; t2; ) =
e (S
(j)
1 (t1)+S
(j)
2 (t2))
e 2S
(j)
(1;2)
(t1;t2;)(e    1)
[f
(j)
1 (t1)][f
(j)
2 (t2)] (4.8)
S
(j)
(1;2)(t1; t2; ) =  
1

log
(
1 +
(e S
(j)
1 (t1)   1)(e S(j)2 (t2)   1)
e    1
)
(4.9)
The density survival and hazard functions of the minimum T are given by
f (j) (t; ) =
e S
(j)
1 (t)(e S
(j)
2 (t)   1)
e C(j)(S
(j)
1 (t);S
(j)
2 (t);)(e (j)   1)
f
(j)
1 (t) (4.10)
+
e S
(j)
2 (t)(e S
(j)
1 (t)   1)
e C(j)(S
(j)
1 (t);S
(j)
2 (t);)(e    1)
f
(j)
2 (t);
S(j) (t; ) = C(S
(j)
1 (t); S
(j)
2 (t)) = S
(j)
(1;2)(t; t; )
(j) (t; ) =
f
(j)
 (t; )
S
(j)
 (t; )
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Hence, in order to compute ARE(Z; Z)we need to specify:
 f (0)1 (t) (S(0)1 (t)): The marginal density (survival) function of T1 for group 0.
 f (0)2 (t) (S(0)2 (t)): The marginal density (survival) function of T2 for group 0.
 : The copula association parameter between T1 and T2.
 HR1: The constant hazard ratio HR1 = (1)1 (t)=(0)1 (t).
 f (1)1 (t) (S(1)1 (t)): The marginal density (survival) function of T1 for group 1.
 f (1)2 (t) (S(1)2 (t)): The marginal density (survival) function of T2 for group 1.
Regarding the marginal laws of T1 and T2, the Weibull distributions were cho-
sen because they are widely used in Survival analysis due to its flexibility, allowing
decreasing, constant and increasing hazard functions.
Hence, for both treatment groups (j = 0; 1) the survival function is given by:
S
(j)
k (t) = expf (t=b(j)k )
(j)
k g, (k = 1; 2 depending if we refer to T1 or T2)
where b(j)1 , b
(j)
2 are the scale parameters and 
(j)
1 , 
(j)
2 are the shape parameters.
The shape parameters are chosen equal for both groups, that is (0)1 = 
(1)
1 = 1 and

(0)
2 = 
(1)
2 = 2, so that the assumption of proportionality of the hazards holds.
Denoting by p1 and p2 the probabilities of observing E1 and E2 in group 0 (assum-
ing that end-of-study censoring at time  is the only censoring cause) they are related
to the marginal law of T1 and the bivariate law of (T1; T2) in group 0 as follows:
p1 = 1  S(0)1 (1) (Fixing  = 1 (Assumption 2))
p2 =
Z 
0
Z 1
v
f
(0)
(1;2)(u; v; )dudv
where f (0)(1;2)(u; v; ) is the joint density of (T1; T2) in group 0 and has been defined in
(4.8).
We can relate the scale parameters b(0)1 and b
(0)
2 to p1 and p2 as follows:
b
(0)
1 =
1
(  log(1 p1))1=1 .
and b(0)2 is a function of the joint density f
(0)
(1;2)(; ; ) and it is found as the solution of
equation p2 =
R 1
0
R1
v
f
(0)
(1;2)(u; v; )dudv.
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On the other hand, the scale parameters b(1)1 , b
(1)
2 , for group 1 are computed so that
the assumption of proportionality of the hazards holds, that is, b(1)1 and b
(1)
2 are such
that:
HR1 =

(1)
1 (t)

(0)
1 (t)
and HR2 =

(1)
2 (t)

(0)
2 (t)
.
Summarizing, in order to calculate the ARE in terms of interpretable parameters we
will have to specify:
1. The marginal parametric laws for the time T1 to the primary endpoint E1 and
for the time T2 to the secondary endpoint E2 for both treatment groups 0 and 1,
2. The probability p1 of an uncensored T1 from group 0,
3. The probability p2 of an uncensored T2 from group 0,
4. The treatment effect of T1jX = 1 versus T1jX = 0 given by the hazard ratioHR1,
5. The treatment effect of T2jX = 1 versus T2jX = 0 given by the hazard ratioHR2,
6. The association between T1 and T2 evaluated by means of Spearman’s correla-
tion parameter  ( is uniquely determined by the copula association parameter
).
Note that the above parameters are all easily interpretable for physicians and in-
vestigators. Interpretability is important because investigators will have to decide a
priori which are the most plausible values for p1, p2, HR1, HR2 and  and, based on
those, the decision to adopt or not a composite endpoint will have to be made on ARE
results.
In this Master Thesis we choose 1 = 1; 2 and 2 = 1; 2 representing constant and
increasing hazard functions and  ranging from 0.15 to 0.75. Regarding the rest of the
necessary parameters to compute ARE (p1; p2; HR1 and HR2) a literature search has
been done to get a realistic range of values used in stent cardiovascular articles.
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Chapter 5
Stent literature search
In order to knowwhich is the range of the common values for the parameters needed
to compute the ARE (as developed in chapter 4) for stent cardiovascular studies, we
have followed a structured search. Online Pubmed database searcher was used to
find current clinical trial articles submitted in the last three years and focused in the
stenting clinical trials area.
Furthermore, a boolean strategy was necessary to enclose the results. The main
logical strategy was:
(STENT OR STENTING) AND
(”RISK RATIO”OR ”RELATIVE RISK”OR RROR ”HAZARDRATIO”ORHR)AND
(MACE ORMACCE)
The two first keywords represent the specific medical area of the search. Since the
parameters are related to time-to-event (survival) analysis, we included Hazard Ratio
and its acronym (HR). Moreover, keywords about Relative Risk and its acronym (RR)
were included in order to amplify the focus and get those articles that use relative
risk or RR to refer to the hazard ratio.
We have followed the advise of an expert biostatistician in cardiovascular stud-
ies, Professor Sharon-Lise Normand from Harvard University, and use the acronyms
MACE and MACCE to refer to the composite endpoints which are commonly used
in stenting clinical trials. The main single endpoints included in MACE and MACCE
are: Cardiac death, Target Vessel Revascularizatio (TVR), Myocardial Infarction (MI)
and Stroke.
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5.1 Papers Identified as Candidates for Application
A total of 27 papers from Pubmed searcher database were obtained (see Figure 5.1).
Among these 27 papers, 5 of them have not been considered because they either were
not based as a clinical trial or they were not a doing survival analysis.
Unfortunately, even with the help of Professors Normand andOlga Julia` (from the
department of statistics, Universitat de Barcelona) we were not able to obtain 4 papers
from EuroIntervention journal and we have restricted our study to the 18 papers left.
Id. Authors
TITLE
Journal
Year of 
publication Vol. Pages
1 Tavassoli N. et al. High maintenance dosage of clopidogrel is associated with a reduced 
risk of stent thrombosis in clopidogrel-resistant patients.
Am J Cardiovasc Drugs. 2010 10(1) 29-35
2 Buszman P. et al. Percutaneous versus surgical revascularization for multivessel 
coronary artery disease: a single center 10 year follow-up of SOS trial 
patients.
Catheter Cardiovasc Interv. 2009 74(3) 420-6
3 Ge YG. et al. Long-term efficacy of sirolimus-eluting stents (Cypher) versus bare 
metal stents for patients with ST-segment elevation myocardial 
infarction
Zhonghua Xin Xue Guan Bing Za Zhi. 2008 36(2) 108-12
4 Okada T. et al. One-year clinical outcomes of dialysis patients after implantation with 
sirolimus-eluting coronary stents.
Circ J. 2008 72(9) 1430-5
5 Chen SL. et al. Comparison between the NERS (New Risk Stratification) score and the 
SYNTAX (Synergy between Percutaneous Coronary Intervention with 
Taxus and Cardiac Surgery) score in outcome prediction for 
unprotected left main stenting.
JACC Cardiovasc Interv. 2010 3(6) 632-41
6 Song YB. et al. Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary 
bifurcations results: from the COBIS (Coronary Bifurcation Stenting) 
Registry.
J Am Coll Cardiol. 2010 55(16) 1743-50
7 Sheiban I. et al. Sex-related differences in patients undergoing percutaneous 
unprotected left main stenting.
EuroIntervention. 2010 5(7) 795-800
8 Stojkovic S. et al. Systemic rapamycin without loading dose for restenosis prevention 
after coronary bare metal stent implantation.
Catheter Cardiovasc Interv. 2010 75(3) 317-25
9 Palmerini T. et al. Impact of bifurcation technique on 2-year clinical outcomes in 773 
patients with distal unprotected left main coronary artery stenosis 
treated with drug-eluting stents.
Circ Cardiovasc Interv. 2008 1(3) 185-92
10 Balducelli M. et al. Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-
eluting stents for patients with diabetes: results of the Registro 
Regionale AngiopLastiche Emilia-Romagna Registry.
Catheter Cardiovasc Interv. 2010 75(3) 327-34
11 Di Lorenzo E. et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-
segment elevation myocardial infarction: four year results of the 
PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary 
angiOplasty (PASEO) randomized trial.
Am Heart J. 2009 158(4) e43-50
12 Wykrzykowska JJ. et al. Impact of vessel size on angiographic and clinical outcomes of 
revascularization with biolimus-eluting stent with biodegradable 
polymer and sirolimus-eluting stent with durable polymer the LEADERS 
trial substudy.
JACC Cardiovasc Interv. 2009 2(9) 861-70
13 Wykrzykowska JJ. et al. Biolimus-eluting biodegradable polymer versus sirolimus-eluting 
permanent polymer stent performance in long lesions: results from the 
LEADERS multicentre trial substudy.
EuroIntervention. 2009 5(3) 310-7
14 Katritsis DG. et al. Comparison of long versus short ("spot") drug-eluting stenting for long 
coronary stenoses.
Am J Cardiol. 2009 104(6) 786-90
15 Mehran R. et al. Bivalirudin in patients undergoing primary angioplasty for acute 
myocardial infarction (HORIZONS-AMI): 1-year results of a 
randomised controlled trial.
Lancet. 2009 374(9696) 1149-59
16 Gyöngyösi M. et al. 2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) 
registry beyond the SYNTAX (synergy between percutaneous coronary 
intervention with TAXUS and cardiac surgery) study.
JACC Cardiovasc Interv. 2009 2(8) 718-27
17 Saia F. et al. Patient selection to enhance the long-term benefit of first generation 
drug-eluting stents for coronary revascularisation procedures. Insights 
from a large multicentre registry.
EuroIntervention. 2009 5(1) 57-66
18 Nfor T. et al. Comparing long-term outcomes between drug-eluting and bare-metal 
stents in the treatment of cardiac allograft vasculopathy.
Catheter Cardiovasc Interv. 2009 74(4) 543-9
19 Umeda H. et al. Safety and efficacy of 2.5-mm sirolimus-eluting stent implantation at 
lower deployment pressures in very small vessels (<2.5 mm).
Coron Artery Dis. 2009 20(2) 163-8
20 Novack V. et al. Multivessel drug-eluting stenting and impact of diabetes mellitus--a 
report from the EVENT registry.
Catheter Cardiovasc Interv. 2009 73(7) 874-80
21 Garro N. et al. Very late thrombosis in acute myocardial infarction: drug-eluting versus 
uncoated stents.
EuroIntervention. 2008 4(3) 324-30
22 Lee MS. et al. Multicenter international registry of unprotected left main coronary 
artery percutaneous coronary intervention with drug-eluting stents in 
patients with myocardial infarction.
Catheter Cardiovasc Interv. 2009 73(1) 15-21
23 Kim JS. et al. Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for 
long-term cardiac adverse events in diabetic patients: the Korean 
Multicenter Angioplasty Team (KOMATE) Registry.
Catheter Cardiovasc Interv. 2008 72(5) 601-7
24 Bertrand OF. et al. Effects of intracoronary compared to intravenous abciximab 
administration in patients undergoing transradial percutaneous 
coronary intervention: A sub-analysis of the EASY trial.
Int J Cardiol. 2009 136(2) 165-70
25 Bertrand OF. et al. One-year clinical outcome after abciximab bolus-only compared with 
abciximab bolus and 12-hour infusion in the Randomized EArly 
Discharge after Transradial Stenting of CoronarY Arteries (EASY) 
Study.
Am Heart J. 2008 156(1) 135-40
26 Billinger M. et al. Two-year clinical outcome after implantation of sirolimus-eluting and 
paclitaxel-eluting stents in diabetic patients.
Eur Heart J. 2008 29(6) 718-25
27 Brodie BR. et al. Outcomes with drug-eluting stents versus bare metal stents in acute 
ST-elevation myocardial infarction: results from the Strategic 
Transcatheter Evaluation of New Therapies (STENT) Group.
Catheter Cardiovasc Interv. 2008 72(7) 893-900
Figure 5.1: Papers identified as candidates for application. Colored: available and selected articles. Crossed out:
ruled out articles.
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5.2 Description of the Clinical Studies and their End-
points
Since the main goal of this thesis is to recommend whether to add a secondary end-
point E2 to the already considered primary endpoint E1, we are interested in several
plausible combinations of combined endpoints E1[E2. We are therefore describing in
Figure 5.2 the primary endpoints used in the chosen clinical trial together with the list
of their individual components of the composite endpoints. Each row of the database
is represented by one or several rows depending on whether or not sub-group analy-
sis were considered in each paper or more than one primary endpoint was specified.
The sample size of each treatment groupwere annotated. We also describe the time to
follow-up inmonths and how is calculated in each paper (mean, median or minimum
time for each patient).
Note that in half of the papers a Propensity-adjusted Cox regression were used to
adjust the nonrandomized study with some possible confounding variables. How-
ever, since the aim of this thesis is to obtain a real world range of values for the
different parameters in cardiovascular studies when using stents, we do not attempt
to validate neither criticize the statistical analysis.
The last two columns include the reported p-values and whether or not statisti-
cal differences between treatments were found. We observe that the majority end-
points are composites, but not always statistical differences between treatments were
achieved.
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Article 
ident.
n1 (control) n2
Time to follow-
up (months)
Randomized Subgroup (when applicable)
Primary endpoint in the article 
(and their components)
Type of endpoint p-value
Significant     
(95% confidence)
2 50 50 115,2 (mean) Yes RR Not a composite <0,05 Yes
4 80 124 12 (min.) Yes *Cardiac death, MI, ST, TLR Composite <0,05 Yes
6 562 1033 22 (median) No Overall Population *Cardiac death, MI, TLR Composite <0,05 Yes
6 562 1033 22 (median) No Propensity-matched population *Cardiac death, MI, TLR Composite <0,05 Yes
8 40 40 6,8 (mean) Yes
In-stent angiographic binary 
restensosis 
Not a composite <0,05 Yes
8 40 40 6,8 (mean) Yes
In-segment angiographic binary 
restensosis 
Not a composite <0,05 Yes
9 456 317 24 (min.) No *Death, MI, TLR Composite <0,05 Yes
10 606 339 33,1 (median) No *AMI, Death, TVR Composite <0,05 Yes
11 90 90 12 (min.) Yes BMS vs PES (1 year outcome) TLR Not a composite <0,05 Yes
11 90 90 41,1 (mean.) Yes BMS vs PES (4 years outcome) TLR Not a composite <0,05 Yes
12 434 429 12 (min.) Yes Small vessell size *Death, MI, TVR Composite 0,89 No
12 272 267 12 (min.) Yes Large vessell size *Death, MI, TVR Composite 0,2 No
12 133 154 12 (min.) Yes Mixed vessell size *Death, MI, TVR Composite 0,57 No
14 90 89 36 (min.) Yes
*Cardiac death, Ischemia, MI, 
ST, TLR
Composite <0,05 Yes
15 1802 1800 12 (min.) Yes
*Death, Major bleeding, MI, 
Stroke, TVR
Composite <0,05 Yes
15 1802 1800 12 (min.) Yes *Death, MI, Stroke, TVR Composite >0,05 No
18 19 25 12 (min.) No ISR Not a composite <0,05 Yes
19 118 126 12 (min.) No *Death, MI, TLR Composite 0,002 Yes
20 256 466 12 (min.) Yes *Death, MI, RR Composite >0,05 No
23 206 428 38 (mean) No *Cardiac death, MI, TVR Composite >0,05 No
24 208 797 1 (min.) No 30 days of follow-up *Death, MI, TVR Composite >0,05 No
24 208 797 6 (min.) No 6 months of follow-up *Death, MI, TVR Composite <0,05 Yes
24 208 797 12 (min.) 1 year of follow-up *Death, MI, TVR Composite >0,05 No
25 504 501 12 (min.) Yes
*Access site complication, Death, 
Major bleeding, MI, 
Rehospitalization, Severe 
thrombocytopenia, TVR
Composite <0,05 Yes
26 509 503 24 (min.) Yes Diabetic patients *Cardiac death, MI, TLR Composite >0,05 No
26 509 503 24 (min.) Yes Non-diabetic patients *Cardiac death, MI, TLR Composite <0,05 Yes
27 548 1292 9 (min.) No Outcomes at 9 months *Death, MI, TVR Composite >0,05 No
27 548 1292 24 (min.) No Outcomes at 2 years *Death, MI, TVR Composite >0,05 No
Figure 5.2: Primary endpoints used in the literature. n1 and n2 stands for the sample size for the control and
treatment group respectively.
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No information about Spearman’s correlation between time to events were found
in literature. However, this information could be assessed, up to certain degree, from
physicians in each study based on their medical experience. Furthermore, as we will
see below, a large range of values were assigned to Spearman’s  correlation coeffi-
cients in order to evaluate how the ARE computations depend upon them.
All the collected information has been analyzed and summarized with SPSS (v15)
statistical program. For more detailed results, see some descriptives outputs about
this database in Appendix A.
In the stent clinical trials many studies based their results on the comparison of
a composite endpoint known as MACE (Major Adverse Cardiac Events). But when
studying which are the components of MACE we find that there is not a unique def-
inition. Most of the studies include Death, Myocardial Infarction and Target Vessel
Revascularization in MACE. However, as wee see in Figure 5.3 other different com-
binations of events are used to define MACE for the study. Authors referred to the
composite MACCE (Major Cardiac Cardiovascular and Cerebrovascular Events) as
Death, Myocardial Infarction, Repeat Revascularization and Stroke, and they referred
to the composite NACE (Net Adverse Clinical Events) as Death, Major bleeding, My-
ocardial Infarction, Stroke and Target Vessel Revascularization. And some authors
did not use a particular name for other composites.
COMPOSITE NAME
TotalMACCE MACE NACE NO NAME
Endpoint *Access site complication, 
Death, Major bleeding, MI, 
Rehospitalization, Severe 
thrombocytopenia, TVR
0 0 0 1 1
*AMI, CHF,Death, ISR, 
Retransplantation, TVR
0 2 0 0 2
*AMI, Death 0 0 0 3 3
*AMI, Death, TVR 0 3 0 0 3
*Cardiac death, Ischemia, 
MI, ST, TLR
0 2 0 0 2
*Cardiac death, MI 0 0 0 2 2
*Cardiac death, MI, ST, TLR 0 2 0 0 2
*Cardiac death, MI, TLR 0 4 0 0 4
*Cardiac death, MI, TVR 0 1 0 0 1
*Death, Major bleeding, MI, 
Stroke, TVR
0 0 1 0 1
*Death, MI 0 0 0 7 7
*Death, MI, RR 0 1 0 0 1
*Death, MI, RR, Stroke 1 0 0 0 1
*Death, MI, ST 0 2 0 0 2
*Death, MI, Stroke, TVR 0 2 0 0 2
*Death, MI, TLR 0 2 0 0 2
*Death, MI, TVR 0 13 0 0 13
*MI, Death 0 0 0 1 1
Total 1 34 1 14 50
 
Figure 5.3: Elements of composite endpoints and the names used in the literature.
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Hence, we have distinguished the following single endpoints as candidates for E1 (or
E2) (in alphabetical order):
 Access site complication
 Acute Myocardial Infarction (AMI)
 Cardiac death
 Congestive heart failure
 Death (any cause)
 Ischemia
 In-Stent Restenosis
 Major bleeding
 Myocardial Infarction (MI)
 Rehospitalization
 Retransplantation
 Repeat Revascularization (RR)
 Severe Thrombocytopenia
 Stent Thrombosis (ST)
 Stroke
 Target Lesion Revascularization (TLR)
 Target Vessel Revascularization (TVR)
We remark that the composite endpoint that these studies are using as primary
endpoint to test the efficacy of the given treatment can be quite different. However,
as we see in Figure 5.4, Death (or cardiac death) is always included, Myocardial In-
farction or Acute Myocardial Infarction are also always included and Target Lesion
Revascularization and Target Vessel Revascularization are almost always included.
Other events such as Stroke, Stent Thrombosis and Repeat Revascularization are only
included as primary endpoints in some studies.
Which the aim of assessing the values of the parameters used to each single event
we have combined Cardiovascular death and Death from any cause in a single event
Death since based in our data we cannot split these two cases. Analogously we have
combined Myocardial Infarction and Acute Myocardial Infarction.
Hence, based on the above, Death (any cause) and Myocardial Infarction (includ-
ing Acute Myocardial Infarction) were considered as a unique primary endpoint
of a general composite since they are common in all the composites found. And
secondary endpoints of a general composite where set as (Target Vessel Revascu-
larization, Target Lesion Revascularization, Stent Thrombosis, Stroke and Repeat
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 Frequency 
 *Access site complication, 
Death, Major bleeding, MI, 
Rehospitalization, Severe 
thrombocytopenia, TVR 
1 
*AMI, Death, TVR 1 
*Cardiac death, Ischemia, 
MI, ST, TLR 
1 
*Cardiac death, MI, ST, TLR 1 
*Cardiac death, MI, TLR 4 
*Cardiac death, MI, TVR 1 
*Death, Major bleeding, MI, 
Stroke, TVR 
1 
*Death, MI, RR 1 
*Death, MI, Stroke, TVR 1 
*Death, MI, TLR 2 
*Death, MI, TVR 8 
Total 22 
 
 
Figure 5.4: Frequency of the composite primary endpoints and their elements.
Revascularization). Since the primary endpoint of the composite includes a terminat-
ing event (Death) and any of the secondary endpoints does not, as we see in chapter
3 we are in the Case 3 situation (see Figure 4.1 in chapter 4).
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5.3 Obtaining the RangeValues for the Probabilities and
Hazard Ratios
Taking into account the primaries and secondaries endpoints considered to set a gen-
eral composite endpoint we need to specify their range of values for probabilities
and hazard ratios. In Figure 5.5 we provide the probabilities of observing each end-
point found in literature together with their hazard ratios for the first articles (see in
Appendix B the entire table).
Article ident. Endpoint Type of endpoint
Probability 
(x 100)
Hazard 
Ratio
2 RR Primary Endp. 42,00
2 *Death, MI, RR, Stroke Composite and secondary endp. 72,00
2 Death Secondary Endp. 18,00
2 MI Secondary Endp. 10,00
2 Stroke Secondary Endp. 8,00
2 Cardiac death Secondary Endp. 8,00
2 LVEF Secondary Endp. 58,00
4 *Cardiac death, MI, ST, TLR Composite and primary endp. 38,20 0,7
4 Cardiac death Secondary Endp. 11,90
4 Sudden/unexplained death Secondary Endp. 5,30
4 MI Secondary Endp. 0,00
4 ST Secondary Endp. 0,80
4 TLR Secondary Endp. 30,90
4 Death Secondary Endp. 19,80
4 *Cardiac death, MI, ST, TLR Composite and secondary endp. 4,10
4 Cardiac death Secondary Endp. 4,10
4 Sudden/unexplained death Secondary Endp. 0,80
4 MI Secondary Endp. 0,00
4 ST Secondary Endp. 0,80
4 TLR Secondary Endp. 0,80
4 Death Secondary Endp. 4,80
6 *Cardiac death, MI, TLR Composite and primary endp. 8,70 0,545
6 Cardiac death Secondary Endp. 0,40 2,89
6 MI Secondary Endp.
6 TLR Secondary Endp. 6,80 0,54
6 *Cardiac death, MI Composite and secondary endp. 2,50 0,83
6 TVR Secondary Endp. 8,40 0,57
6 Periprocedural enzyme elevation Secondary Endp. 17,30
6 ST Secondary Endp. 0,70
6 *Cardiac death, MI, TLR Composite and primary endp. 8,60 0,52
6 Cardiac death Secondary Endp. 0,50 2,675
6 MI Secondary Endp.
6 TLR Secondary Endp. 7,10 0,47
6 TVR Secondary Endp. 8,80 0,54
6 Periprocedural enzyme elevation Secondary Endp. 16,50
6 ST Secondary Endp. 0,50
8 In-stent angiographic binary restensosis Primary Endp. 51,35
8 In-segment angiographic binary restensosis Primary Endp. 48,65
8 TLR Secondary Endp. 22,70
8 TVR Secondary Endp. 22,70
8 *Death, MI, Stroke, TVR Composite and secondary endp. 22,70
Figure 5.5: Sample table for the first four articles with their probabilities and hazard ratios of each endpoint.
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We see in Figure 5.6 that the probability values mixing both primary and sec-
ondary endpoints for the general composite ranges from 0% to 30% in 98% of cases.
We provide the values of the hazard ratios in Figure 5.7.
 
 
 
PROB_T2
10 3,8 7,7 7,7
11 4,2 8,5 16,2
43 16,4 33,1 49,2
36 13,7 27,7 76,9
17 6,5 13,1 90,0
4 1,5 3,1 93,1
4 1,5 3,1 96,2
2 ,8 1,5 97,7
3 1,1 2,3 100,0
130 49,6 100,0
132 50,4
262 100,0
< 0.05 %
0.05 - 1 %
1 - 5%
5 - 10%
10 - 15%
15 - 20%
20 - 25%
25 - 30%
>30%
Total
Válidos
SistemaPerdidos
Total
Frecuencia Porcentaje
Porcentaje
válido
Porcentaje
acumulado
Figure 5.6: Probabilities (by intervals) for both primary and secondary endpoints in the general composite.
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 HR_T
1 ,4 1,7 1,7
1 ,4 1,7 3,4
1 ,4 1,7 5,2
1 ,4 1,7 6,9
1 ,4 1,7 8,6
2 ,8 3,4 12,1
1 ,4 1,7 13,8
1 ,4 1,7 15,5
1 ,4 1,7 17,2
1 ,4 1,7 19,0
1 ,4 1,7 20,7
1 ,4 1,7 22,4
2 ,8 3,4 25,9
2 ,8 3,4 29,3
1 ,4 1,7 31,0
2 ,8 3,4 34,5
1 ,4 1,7 36,2
4 1,5 6,9 43,1
1 ,4 1,7 44,8
1 ,4 1,7 46,6
2 ,8 3,4 50,0
2 ,8 3,4 53,4
1 ,4 1,7 55,2
1 ,4 1,7 56,9
2 ,8 3,4 60,3
2 ,8 3,4 63,8
1 ,4 1,7 65,5
1 ,4 1,7 67,2
1 ,4 1,7 69,0
1 ,4 1,7 70,7
1 ,4 1,7 72,4
1 ,4 1,7 74,1
2 ,8 3,4 77,6
2 ,8 3,4 81,0
1 ,4 1,7 82,8
1 ,4 1,7 84,5
1 ,4 1,7 86,2
2 ,8 3,4 89,7
1 ,4 1,7 91,4
2 ,8 3,4 94,8
1 ,4 1,7 96,6
1 ,4 1,7 98,3
1 ,4 1,7 100,0
58 22,1 100,0
204 77,9
262 100,0
,17
,21
,24
,27
,28
,29
,38
,39
,40
,42
,44
,45
,47
,48
,50
,54
,55
,57
,57
,64
,67
,68
,71
,72
,75
,76
,80
,81
,83
,85
,85
,89
,92
,93
,98
1,01
1,02
1,06
1,08
1,21
1,26
1,31
1,61
Total
Válidos
SistemaPerdidos
Total
Frecuencia Porcentaje
Porcentaje
válido
Porcentaje
acumulado
Figure 5.7: Hazard ratios for both primary and secondary endpoints in the general composite.
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In order to get a parsimonious analysis, we crossed the information between the
probabilities of occurrence of the primary endpoint p1 versus their Hazard RatiosHR1
(see Figure 5.8). This information allows us to avoid unnecessary combinations that
we will not see in real world studies. We observe that values of p1 in the neighbor-
hood of 0.035 act together with HR1 around 0.5, while p1 near 0.05 appear together
with HR1 = 0:8, p1 near 0.09 appear together with HR1 = 0:9 and p1 near 0.125 ap-
pear together with HR1 = 0:7. And this provides the combination of values for the
primary endpoint given in Table 5.1.
Figure 5.8: Probability of the primary endpoint versus their Hazard Ratio. Outliers were ruled out.
p1 HR1
I 0.035 0.5
II 0.05 0.8
III 0.09 0.9
IV 0.125 0.7
Table 5.1: Combinations of values for the primary endpoint. p1 stands for the probability of occurrence of the
primary endpoint and HR1 stands for the hazard ratio of the primary endpoint.
Parameters values for secondary endpoints of the composite were chosen in the same
way (see Figure 5.9). See combinations for the secondary endpoint in table 5.2.
p2 HR2
I 0.1 0.55
II 0.1 0.8
III 0.15 0.3
III 0.15 0.35
III 0.20 0.25
Table 5.2: Combinations of values for the secondary endpoint. p2 stands for the probability of occurrence of the
secondary endpoint and HR2 stands for the hazard ratio of the secondary endpoint.
Observations of p2 with lower percentage than 5%were ruled out since investiga-
tors may not be interested in an endpoint that adds so few observed events for the
clinical trial.
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Figure 5.9: Probability of the secondary endpoint versus their Hazard Ratio. Outliers were ruled out.
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The combination of values for (p1; HR1) and (p2; HR2) given in Tables 5.1 and
5.2, would yield 20 plausible combinations for the composite endpoint. However,
to increase the scope of the present study we have combined all the possibilities for
p1; p2; HR1 and HR2 as it is shown in Table 5.3.
p1 0.035 0.05 0.09 0.125
p2 0.1 0.15 0.2
HR1 0.5 0.7 0.8 0.9
HR2 0.25 0.3 0.35 0.55 0.8
Table 5.3: p1 and p2 stands for the probability of occurrence of the primary and secondary endpoint respectively.
And HR1 and HR2 stands for the hazard ratio of the primary and secondary endpoint respectively.
We are using the values given in Table 5.3 to feed the Maple programs and to
obtain the ARE for each possible combination as it is presented in chapter 6.
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Chapter 6
Specific Analysis for Stents
6.1 Setting for the Computations and executionwithMaple
In chapter 5 we have described which are the more plausible values for p1 and p2,
HR1 and HR2, consistent with those found in stent clinical trials. These values to-
gether with the chosen values for the shape parameters for the Weibull marginal
laws (j = 1 representing constant hazards and j = 2 for increasing hazards) and
an exhaustive election for Spearman’s rank correlation between the primary and the
secondary endpoint, form the bases of our first exploratory analysis and are given in
Table 6.1.
1 1 2
2 1 2
p1 0.035 0.05 0.09 0.125
p2 0.1 0.15 0.2
 0.15 0.25 0.35 0.45 0.55 0.65 0.75
HR1 0.5 0.7 0.8 0.9
HR2 0.25 0.3 0.35 0.55 0.8
Table 6.1: Range of values chosen for each parameter. p1 and p2 stands for the probability of occurrence of
the primary and secondary endpoint respectively. HR1 and HR2 stands for the hazard ratio of the primary
and secondary endpoint respectively. 1 and 2 are the shape parameters and  the Spearman’s rank correlation
between T1 and T2.
All the computations were done with Maple (v12) (see code in the Appendix C)
and were based on Go´mez and Lagakos method (2011) following the steps below:
 The the range of values of Spearman’s rank correlation  are introduced and
for each one the corresponding Frank’s copula association parameter  is calcu-
lated.
 Sets of values for (1; 2; p1; p2; HR1; HR2) as shown in Table 6.1 are provided.
For each possible combination the ARE is computed following the method de-
scribed in chapter 4.
 The resulting values of the ARE for each parameter combination are written in a
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database and used for the analysis of the convenience of choosing the composite
endpoint versus the primary endpoint.
6.2 Preliminary Results
Preliminary analysis of the ARE values show that the Asymptotic Relative Efficiency
for a given combination (p1; p2; HR1; HR2; ) is analogous for the 4 different choices
of (1; 2). Thus, we concluded that the behavior of ARE is independent of whether
or not the marginal hazard functions are constant or increasing. For the moment no
other choices for 1 and 1 are considered.
We present the results for a particular combination of 1 = 2 = 1 and for each
of the 48 scenarios that the possible values of p1; p2 and HR1 yield. For each scenario
we plot the 6 curves corresponding to the 6 different values of the relative treatment
effect on E2 (HR2) in cartesian axis. The abscissae is used for Spearman’s  while
the ARE(Z; Z) are in a logarithmic scale in the ordinate. We use a logarithmic scale
to faithfully represent the significance of the relative asymptotic efficiency, as, for
example, an ARE(Z; Z) = 2 is as relevant as an ARE(Z; Z) = 0:5. That is, the
distance from a point with ARE(Z; Z) = 2 to 1 is the same as the distance from a
point with ARE(Z; Z) = 0:5.
One instance of these plots is given for scenario 25 in Figure 6.1. In this case the
probability of observing a primary endpoint is 0.09 and of observing a secondary
endpoint is 0.1 for a relative treatment effect on E1 equal to 0.5. We observe that
irrespective of the degree of association between T1 and T2 we will always choose the
composite endpoint when the effect on E2 is very low (HR2 = 0:8).
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Figure 6.1: Scenario 25: Values of the ARE depending on the Spearman’s rank correlation between T1 and T2
and on the Hazard Ratios of the secondary endpoint HR2. Fixed values: 1 = 2 = 1;HR1 = 0:5; p1 = 0:09
and p2 = 0:1. HR1 and HR2 stands for the hazard ratios of the primary and secondary endpoints respectively
and p1 and p2 stands for the probability of occurrence of the primary and secondary endpoints respectively.
Close study of these 48 plots reveals that the composite endpoint should always
be used if HR1  0:8 and HR2  0:35 irrespective of the values of (p1; p2; ). We
observe as well that values of HR1 chosen to 0.5 and of HR2 larger than 0.55 provide
often ARE values in the vicinity of 1, for this reason new values forHR1 andHR2 are
established as shown in Table 6.2.
Hence, the new range of parameters were given by:
1 1
2 1
p1 0.035 0.05 0.09 0.125
p2 0.1 0.15 0.2
 0.15 0.25 0.35 0.45 0.55 0.65 0.75
HR1 0.5 0.6 0.7 0.8
HR2 0.4 0.5 0.6 0.7 0.8 0.9
Table 6.2: Range of values chosen for each parameter.
6.3 Results and Guidelines
Regarding Go´mez and Lagakos paper, the range of parameters values of the hazard
ratios HR1 and HR2 used were similar to the hazard ratios used in this thesis, and
the range of Spearman’s rank correlation  was the same. However, probabilities p1
and p2 were higher (0.5 and 0.7 for both) compared to our probability parameters
values (see table 6.2). As a general summary about the conclusions of Go´mez and
Lagakos obtained for the case 3, they observed that the ARE values decrease when-
ever the correlation between the two endpoints increases and when the relative effect
on treatment on the secondary endpoint is smaller. The recommendation to use the
composite endpoint is clear when the relative treatment effect HR2 on the secondary
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Figure 6.2: Scenario 42: Values of the ARE depending on the Spearman’s rank correlation between T1 and T2
and on the hazard ratios of the secondary endpoint. Fixed values: 1 = 2 = 1; HR1 = 0:6; p1 = 0:125 and
p2 = 0:15. HR1 andHR2 stands for the hazard ratios of the primary and secondary endpoints respectively and
p1 and p2 stands for the probability of occurrence of the primary and secondary endpoints respectively.
endpoint is smaller (higher beneficial effect) than on the primary endpoint. How-
ever, when the secondary endpoint has approximately the same relative treatment
effect on treatment, or slightly larger (smaller beneficial effect), than the primary end-
point, the decision on whether or not to use the composite depends on the frequency
of observing each endpoint together whit their correlation.
Regarding the choice of parameters we are studying, we observe a similar pattern
in all 48 scenarios showing that the values of ARE decrease when the Spearman’s
rank correlation between the endpoints increases (see Figure 6.2 as an example). In
Appendix D we present the plots for the 48 scenarios.
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In Figure 6.3 we observe that the percentage of cases in which we should use
the composite (ARE > 1) is higher when the Spearman’s rank correlation value be-
tween the endpoints decreases. However, we observe that the amount of association
between T1 and T2 is not enough on itself to elucidate whether or not to use the com-
posite endpoint, hence the influence of other parameters in the ARE value is studied.
0.350.250.15 0.55 0.65
CE (79%)
ρ
Lower Spearman
correlation between
PE and SE
0.45
ρ
Higher Spearman
correlation between
PE and SE
0.75
CE (78%) CE (77%) CE (76%) CE (73%) CE (71%)CE (74%)
(of 288 cases) (of 288 cases) (of 288 cases) (of 288 cases) (of 288 cases) (of 288 cases) (of 288 cases)
Percentage of situations for which Composite 
endpoint should be used
By rho
Figure 6.3: CE stands for composite endpoint, PE for primary endpoint and SE for secondary endpoint.
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Figure 6.4 shows that as the probability of observing the primary endpoint gets
larger, the need of adding a secondary endpoint and use the composite endpoint is
less relevant, while the secondary endpoint tends to be more necessary when the
probability of being observed gets larger. However, the frequency of observing ei-
ther endpoint is not enough to recommend the composite endpoint over the primary
endpoint.
Percentage of situations for which Composite 
endpoint should be used 
By p1 and p2  
0.05 0.04 0.13 
 68%  72%  80%  83% 
p1 p1 
0.09 
0.1 0.2 
 78%  76%  73% 
p2 p2 
0.15 
A 
B 
(of 504 cases) (of 504 cases) (of 504 cases) (of 504 cases) 
(of 672 cases) (of 672 cases) (of 672 cases) 
Figure 6.4: p1 and p2 stands for the probability of occurrence of the primary and secondary endpoints respec-
tively.
We explore now how do the ARE values behave when combining the frequencies
of observing E1 and E2. In Figure 6.5 we present 4 plots for the 4 possible values of
p1 as a function of p2. We observe that when the probability of observing the primary
endpoint gets larger, the need of adding a secondary endpoint is less relevant for all
the possible values of p2. Again, however we do not have a clear pattern which allow
us to present a general recommendations in terms of (p1; p2) jointly.
48
Percentage of situations for which Composite 
endpoint should be used
By p1 and p2
p1= 0.04
p1= 0.05
p1= 0.09
p1= 0.13
0.1 0.2
83%83%81%
p2 p2
0.15
(of 168 cases) (of 168 cases) (of 168 cases)
0.1 0.2
83%80%76%
p2 p2
0.15
0.1 0.2
74%72%69%
p2 p2
0.15
0.1 0.2
70%67%66%
p2 p2
0.15
Figure 6.5: p1 and p2 stands for the probability of occurrence of the primary and secondary endpoints respec-
tively.
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Figure 6.6 presents the percentage of situations for which the composite endpoint
should be used for the 4 different values of p1 together with the 7 possible values
of Spearman’s rank correlation. We observe that the percentage of cases in which
we should use the composite is higher when the Spearman’s rank correlation value
between the endpoints decreases for each value of the probability of observing the
primary endpoint. Although it is clear that as p1 and  get larger the composite end-
point is less convenient no conclusions results are achieved.
0.350.250.15 0.55 0.65
CE (83%)
ρ
0.45
ρ
0.75
CE (83 %) CE (83 %) CE (83 %) CE (82%) CE (81%)CE (82%)
Percentage of situations for which Composite 
endpoint should be used
By p1 and rho
p1= 0.04
0.350.250.15 0.55 0.65
CE (83%)
ρ
0.45
ρ
0.75
CE (82%) CE (82%) CE (79%) CE (76%) CE (75%)CE (79%)
0.350.250.15 0.55 0.65
CE (78%)
ρ
0.45
ρ
0.75
CE (75%) CE (72%) CE (71%) CE (69%) CE (67%)CE (69%)
(of 72 cases) (of 72 cases) (of 72 cases) (of 72 cases) (of 72 cases) (of 72 cases) (of 72 cases)
0.350.250.15 0.55 0.65
CE (72%)
ρ
0.45
ρ
0.75
CE (71%) CE (71%) CE (69%) CE (63%) CE (61%)CE (67%)
p1= 0.05
p1= 0.09
p1= 0.13
Figure 6.6: CE stands for composite endpoint, p1 stands for the probability of occurrence of the primary endpoint
and rho () stands for the Spearman’s rank correlation between T1 and T2.
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Regarding how the values of the relative treatment effect on the primary endpoint
influence the ARE value, we observe that as it gets larger, hence having less beneficial
effect, adding a secondary endpoint is more convenient (see Figure 6.7 A).
Percentage of situations for which Composite 
endpoint should be used 
By HR1 and HR2 
0.6 0.5 0.8 
 91%  81%  71%  59% 
HR1 HR1 
Higher beneficial effect Lower beneficial effect 
0.7 
0.6 0.5 0.4 0.8 0.9 
 11%  55%  87%  99%  100%  100% 
HR2 HR2 
0.7 
A 
B 
(of 504 cases) (of 504 cases) (of 504 cases) (of 504 cases) 
(of 336 cases) (of 336 cases) (of 336 cases) (of 336 cases) (of 336 cases) (of 336 cases) 
Figure 6.7: HR1 andHR2 stands for the hazard ratios of the primary and the secondary endpoints respectively.
The value of the hazard ratio of the secondary endpoint is by itself relevant (see
Figure 6.7 B). Notice that if the relative treatment effect on E2 gets higher (HR2 
0:5) the composite endpoint should always be used irrespective of the effect that the
treatment has on E1 and irrespective of the frequency of observing E1 or E2.
Figure 6.8 where the plots are presented for joint combinations of HR1 and HR2
present some conclusive results. We observe that irrespective of the correlation be-
tween T1 and T2 and of the frequencies p1 and p2, when theHR2  HR1 the composite
endpoint should always be used. That is, when the treatment effect on the secondary
endpoint is higher or equal to the treatment effect on the primary, we always recom-
mend to use the composite endpoint.
On the other hand, if the treatment effect on E2 is very low (HR2 = 0:9) the com-
posite endpoint should never be used unless perhaps if the effect on E2 is as well very
low.
Finally, those situations where the effect on E2 is slightly lower than on E1 (HR2  
HR1 = 0:1) the recommendations is not clear and should be based on the values of
other parameters and on other clinical considerations.
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Percentage of situations for which Composite 
endpoint should be used 
Higher beneficial effect Lower beneficial effect 
0.6 0.5 0.4 0.8 0.9 
 0%  0%  56%  96%  100%  100% 
HR2 HR2 
0.7 
A) HR1= 0.5 
0.6 0.5 0.4 0.8 0.9 
 0%  33%  93%  100%  100%  100% 
HR2 HR2 
0.7 
B) HR1= 0.6 
0.6 0.5 0.4 0.8 0.9 
 0%  85%  100%  100%  100%  100% 
HR2 HR2 
0.7 
B) HR1= 0.7 
0.6 0.5 0.4 0.8 0.9 
 45%  100%  100%  100%  100%  100% 
HR2 HR2 
0.7 
(of  84 cases) (of 84 cases) (of 84 cases) (of 84 cases) (of 84 cases) (of 84 cases) 
B) HR1= 0.8 
Figure 6.8: HR1 andHR2 stands for the hazard ratios of the primary and the secondary endpoints respectively.
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6.4 Conclusions
We have obtained the Asymptotic Relative Efficiency for parameter values in agree-
ment with those reported in stent cardiovascular clinical trials. We can conclude that
the decision to use a composite endpoint, other thanmedical suitability and consider-
ations, depends basically on the combinations of the hazard ratios of the primary and
secondary endpoints. The following table summarizes these particular combinations:
Use the Primary endpoint when: Use the Composite endpoint when:
HR1 = 0:5 and HR2  0:8 HR2  HR1
HR1 = 0:6 and HR2  0:9 HR2  0:5
HR1 = 0:7 and HR2  0:9 HR1 = 0:5 and HR2  0:5
HR2  HR1 + 0:3 HR1 = 0:6 and HR2  0:6
HR1 = 0:7 and HR2  0:7
HR1 = 0:8 and HR2  0:8
HR1  0:8 and HR2  0:35
Table 6.3: Summary table to decide when it should be better to use a primary endpoint or a composite by the
combinations of the hazard ratios HR1 and HR2.
The main goal of this research is to specialize these findings for the stent cardio-
vascular clinical trials. We are now working on this and we hope to share our find-
ings with experts in this field so that specific guidelines on when it is best to add
stroke, say, to a primary endpoint consisting of Death and Myocardial Infarction are
set for specific frequencies of observing each of the events and specific hazard ratio
values. As an instance, we illustrate this with Brodie paper [5]. In this study they
used a primary composite endpoint consisting of Death, Myocardial Infarction and
Target Vessel Revascularization. The hazard ratios of Death and Myocardial Infarc-
tion were 0.92 and 0.81, respectively, while the hazard ratio of Target Vessel Revas-
cularization was 0.55. We see in Figure 6.8 that for the combination HR1 = 0:8 and
0:5 < HR2 = 0:55 < 0:6 the composite endpoint provides always a higher efficiency,
hence in this particular situation the choice of Death, Myocardial Infarction and Tar-
get Vessel Revascularization as endpoint it was indeed preferable to the choice of, for
instance, Death and Myocardial Infarction as endpoint.
However, ARE results show us that there are other cases where it is better to use
a single endpoint depending on other parameter combinations and these guidelines
could help physicians to decide whether or not use a composite in a particular clinical
trial in the future.
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Chapter 7
Concluding Remarks and Future
Research
This master thesis has brought me a personal grateful experience and an opportunity
to have a deeper understanding of the asymptotic survival theory and their appli-
cability to the stent cardiovascular area. Moreover, I have learnt how to write this
document in LaTeX and how to improve my writing in English. I have also learnt
how to use Maple and refresh my knowledge of SPSS.
I want to remark that this master thesis is a first introductory study that will help
to Professors Guadalupe Go´mez, Urania Dafni and me to submit a contribution to
the 6th EMR-IBS conference in Crete (Greece) on May 2011. In addition, a paper
concerning the application of composite endpoints to the cardiovascular area is in
mind. And this master thesis will be the prelude to develop my Doctoral Thesis
research based in the following issues to carry out:
 Develop recommendations to decide when it is necessary to extend the primary
endpoint to the composite based on the different parameter values amplifying
the possibilities by different tests as weighted log-rank test and other from the
Fleming-Harrington family.
 Study the behavior of the guidelines using other laws for the variable T different
to the Weibull that incorpores other shapes for the risk function (e.g bath-tub
curve).
 From a theoretical point of view, develop different hypothesis if the hazard ra-
tios were not proportional.
 Analyze the better option by means of the relative efficiency in different areas,
as oncology and HIV infection.
 Study the correspondence between the relative efficiency and the sample size
related to the power of the test.
 Develop the statistical repercussions if we treat the T variable as a dicotomy
(e.g. death/no death) rather than the time to an event. Analyze this for a single
endpoint, or a composite endpoint, modeling the analysis with a log-logistic
regression.
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 Create aWeb interface where institutions and companies could help them to de-
cide whether or not to use a composite endpoint based on different parameters
and their relative efficiency results.
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Appendix A
Descriptive Outputs
 Descriptive outputs 
 
  N Minimum Maximum Mean 
Standard 
deviation 
Sample size 262 44 3602 1000,87 1006,143 
n1 (control) 262 19 1802 452,40 499,230 
n2 262 25 1800 548,47 537,226 
Probability 247 ,00 72,00 10,6478 11,24357 
HR 126 ,2 2,9 ,766 ,4243 
      
 
 
 Type of endpoint 
 
  Frequency Percentage 
Valid 
percentage  
Cumulative 
percentage  
 Composite and 
primary endp. 22 8,4 8,4 8,4 
Composite and 
secondary endp. 28 10,7 10,7 19,1 
Primary Endp. 6 2,3 2,3 21,4 
Secondary Endp. 206 78,6 78,6 100,0 
Total 262 100,0 100,0   
 
 
 Significant 
 
  Frequency Percentage 
Valid 
percentage 
Cumulative 
percentage 
   17 6,5 6,5 6,5 
NO 183 69,8 69,8 76,3 
YES 62 23,7 23,7 100,0 
Total 262 100,0 100,0   
 
 
Figure A.1: Descriptive outputs from stent cardiovascular literature search papers.
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Appendix B
Row data in Literature Search
Article ident. Endpoint Type of endpoint Probability HR
2 RR Primary Endp. 42,00
2 *Death, MI, RR, Stroke Composite and secondary endp. 72,00
2 Death Secondary Endp. 18,00
2 MI Secondary Endp. 10,00
2 Stroke Secondary Endp. 8,00
2 Cardiac death Secondary Endp. 8,00
2 LVEF Secondary Endp. 58,00
4 *Cardiac death, MI, ST, TLR Composite and primary endp. 38,20 0,7
4 Cardiac death Secondary Endp. 11,90
4 Sudden/unexplained death Secondary Endp. 5,30
4 MI Secondary Endp. 0,00
4 ST Secondary Endp. 0,80
4 TLR Secondary Endp. 30,90
4 Death Secondary Endp. 19,80
4 *Cardiac death, MI, ST, TLR Composite and secondary endp. 4,10
4 Cardiac death Secondary Endp. 4,10
4 Sudden/unexplained death Secondary Endp. 0,80
4 MI Secondary Endp. 0,00
4 ST Secondary Endp. 0,80
4 TLR Secondary Endp. 0,80
4 Death Secondary Endp. 4,80
6 *Cardiac death, MI, TLR Composite and primary endp. 8,70 0,545
6 Cardiac death Secondary Endp. 0,40 2,89
6 MI Secondary Endp.
6 TLR Secondary Endp. 6,80 0,54
6 *Cardiac death, MI Composite and secondary endp. 2,50 0,83
6 TVR Secondary Endp. 8,40 0,57
6 Periprocedural enzyme elevation Secondary Endp. 17,30
6 ST Secondary Endp. 0,70
6 *Cardiac death, MI, TLR Composite and primary endp. 8,60 0,52
6 Cardiac death Secondary Endp. 0,50 2,675
6 MI Secondary Endp.
6 TLR Secondary Endp. 7,10 0,47
6 TVR Secondary Endp. 8,80 0,54
6 Periprocedural enzyme elevation Secondary Endp. 16,50
6 ST Secondary Endp. 0,50
8 In-stent angiographic binary restensosis Primary Endp. 51,35
8 In-segment angiographic binary restensosis Primary Endp. 48,65
8 TLR Secondary Endp. 22,70
8 TVR Secondary Endp. 22,70
8 *Death, MI, Stroke, TVR Composite and secondary endp. 22,70
9 *Death, MI, TLR Composite and primary endp. 24,70 0,505
9 Cardiac death Secondary Endp. 7,70
9 MI Secondary Endp. 3,50 0,38
9 TLR Secondary Endp. 13,00
9 *MI, Death Composite and secondary endp. 0,38
9 Death Secondary Endp. 9,60
9 Diabetes Secondary Endp. 1,47
9 Acute coronary syndrome Secondary Endp. 1,56
9 Renal dysfunction Secondary Endp. 1,61
9 LVEF Secondary Endp. 0,98
9 Multivessel disease Secondary Endp. 0,8
9 Kissing balloon postdilation Secondary Endp. 0,49
10 *AMI, Death, TVR Composite and primary endp. 24,40 1,01
10 Death Secondary Endp. 9,70 1,02
10 AMI Secondary Endp. 9,20 0,89
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10 TVR Secondary Endp. 14,60 1,06
10 *AMI, Death Composite and secondary endp. 16,30
10 ST Secondary Endp. 1,20 0,42
10 *AMI, Death, TVR Composite and secondary endp. 19,60
10 Death Secondary Endp. 6,90
10 AMI Secondary Endp. 9,20
10 TVR Secondary Endp. 11,50
10 *AMI, Death Composite and secondary endp. 12,40
10 ST Secondary Endp. 1,00
10 *AMI, Death, TVR Composite and secondary endp. 11,40
10 Death Secondary Endp. 3,60
10 AMI Secondary Endp. 4,90
10 TVR Secondary Endp. 6,50
10 *AMI, Death Composite and secondary endp. 7,40
10 ST Secondary Endp. 0,70
11 TLR Primary Endp. 14,40 0,29
11 *Death, MI Composite and secondary endp. 13,30
11 Death Secondary Endp. 6,70
11 ReMI Secondary Endp. 6,70
11 ST Secondary Endp. 1,10
11 *Death, MI, TVR Composite and secondary endp. 24,40 0,42
11 TLR Secondary Endp. 21,10 0,29
11 *Death, MI Composite and secondary endp. 21,10
11 Death Secondary Endp. 12,20 0,76
11 ReMI Secondary Endp. 13,30
11 ST Secondary Endp. 2,20
11 *Death, MI, TVR Composite and secondary endp. 36,70 0,51
11 TLR Primary Endp. 14,40 0,21
11 *Death, MI Composite and secondary endp. 13,30
11 Death Secondary Endp. 6,70
11 ReMI Secondary Endp. 6,70
11 ST Secondary Endp. 1,10
11 *Death, MI, TVR Composite and secondary endp. 24,40 0,42
11 TLR Secondary Endp. 21,10 0,24
11 *Death, MI Composite and secondary endp. 21,10 0,7
11 Death Secondary Endp. 12,20
11 ReMI Secondary Endp. 13,30
11 ST Secondary Endp. 2,20
11 *Death, MI, TVR Composite and secondary endp. 36,70 0,51
12 *Death, MI, TVR Composite and primary endp. 11,80 1,03
12 Death Secondary Endp. 2,30 1,21
12 Cardiac death Secondary Endp. 1,80 1,26
12 MI Secondary Endp. 4,60 1,21
12 TLR Secondary Endp. 7,40 1,31
12 TVR Secondary Endp. 9,90 1,08
12 ST Secondary Endp. 2,80 1,61
12 Target Vessel Failure Secondary Endp. 13,10 1,03
12 *Death, MI, TVR Composite and primary endp. 10,30 0,68
12 Death Secondary Endp. 4,40 0,85
12 Cardiac death Secondary Endp. 3,30 0,68
12 MI Secondary Endp. 4,00 0,92
12 TLR Secondary Endp. 5,10 0,5
12 TVR Secondary Endp. 7,70 0,48
12 ST Secondary Endp. 2,90 0,76
12 Target Vessel Failure Secondary Endp. 11,00 0,57
12 *Death, MI, TVR Composite and primary endp. 14,30 0,83
12 Death Secondary Endp. 3,80 0,68
12 Cardiac death Secondary Endp. 3,80 0,17
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12 MI Secondary Endp. 5,30 2,02
12 TLR Secondary Endp. 11,30 0,44
12 TVR Secondary Endp. 13,50 0,45
12 ST Secondary Endp. 4,50 0,72
12 Target Vessel Failure Secondary Endp. 14,30 0,63
14 *Cardiac death, Ischemia, MI, ST, TLR Composite and primary endp. 20,00 0,41
14 Death Secondary Endp. 2,20
14 MI Secondary Endp. 1,10
14 Restenosis Secondary Endp. 8,90
14 ST Secondary Endp. 0,00
14
Angina and positive dobutamine stress 
echocardiographic result Secondary Endp. 7,80
14 New lesion in same vessel Secondary Endp. 4,40
14 *Cardiac death, Ischemia, MI, ST, TLR Composite and secondary endp. 15,60
14 Death Secondary Endp. 2,20
14 MI Secondary Endp. 1,10
14 Restenosis Secondary Endp. 8,90
14 ST Secondary Endp. 0,00
14
Angina and positive dobutamine stress 
echocardiographic result Secondary Endp. 7,80
14 New lesion in same vessel Secondary Endp. 4,40
15 *Death, Major bleeding, MI, Stroke, TVR Composite and primary endp. 18,30 0,83
15 *Death, MI, Stroke, TVR Composite and primary endp. 11,90 1
15 Major bleeding Secondary Endp. 9,20 0,61
15 Death Secondary Endp. 3,80 0,57
15 Death Secondary Endp. 4,80 0,71
15 Cardiac death Secondary Endp. 3,80 0,57
15 Non cardiac death Secondary Endp. 1,10
15 ReMI Secondary Endp. 4,40
15 Qwave Secondary Endp. 2,10
15 Non-Q wave Secondary Endp. 2,70
15 *Death, MI Composite and secondary endp. 8,50
15 TVR Secondary Endp. 5,90
15 TLR Secondary Endp. 4,50
15 Ischaemic remote TVR Secondary Endp. 2,00
15 Stroke Secondary Endp. 1,20
15 ST Secondary Endp. 3,20
15 ST - definitive Secondary Endp. 2,40
15 ST - probable Secondary Endp. 0,80
15 Protocol major, non-CABG Secondary Endp. 9,20
15 Protocol major, all Secondary Endp. 11,80
15 Blood transfusion Secondary Endp. 4,00
15 TIMI (major or minor) Secondary Endp. 10,20
15 TIMI major Secondary Endp. 5,50
15 TIMI minor Secondary Endp. 4,80
15 GUSTO (life-threatening,severe or moderate) Secondary Endp. 6,00
15 GUSTO life-threatening or severe Secondary Endp. 0,70
15 GUSTO moderate Secondary Endp. 5,40
18 ISR Primary Endp. 12,90
18 In-segment restenosis Secondary Endp. 16,10
18 TVR Secondary Endp. 9,70
18 Death Secondary Endp. 5,30
18 *AMI, CHF,Death, ISR, Retransplantation, TVR Composite and secondary endp. 21,10
18 ISR Secondary Endp. 38,00 0,4
18 ISR with vessels <= 3mm (5 years) Secondary Endp. 55,00 0,37
18 ISR with vessels > 3mm (5 years) Secondary Endp. 18,20
18 ISR Secondary Endp. 38,00
18 In-segment restenosis Secondary Endp. 38,10 0,9
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18 TVR Secondary Endp. 39,40 0,93
18 Death Secondary Endp. 28,00 0,75
18 *AMI, CHF,Death, ISR, Retransplantation, TVR Composite and secondary endp. 49,90 1,09
19 *Death, MI, TLR Composite and primary endp. 27,10 0,32
19 Death Secondary Endp. 0,80
19 MI Secondary Endp. 0,80
19 ST Secondary Endp. 0,80
19 TLR Secondary Endp. 26,30
20 *Death, MI, RR Composite and primary endp. 22,10 1
20 Death Secondary Endp. 3,60
20 MI Secondary Endp. 12,40
20 RR Secondary Endp. 10,40
20 Unrgent PCI Secondary Endp. 8,00
20 TLR Secondary Endp. 6,40
20 nonTLR Secondary Endp. 4,00
20 CABG Secondary Endp. 2,40
23 *Cardiac death, MI, TVR Composite and primary endp. 14,10 0,858
23 ST (definitive) Secondary Endp. 1,90
23 ST (probable) Secondary Endp. 1,50
23 ST (possible) Secondary Endp. 4,90
23 Stent thrombosis (definitive and probable) Secondary Endp. 2,80 0,96
23 Death Secondary Endp. 5,80
23 Cardiovascular death Secondary Endp. 4,90
23 *Cardiac death, MI Composite and secondary endp. 8,30
23 TVR Secondary Endp. 6,80 0,851
23 MI Secondary Endp. 0,67
24 *Death, MI, TVR Composite and primary endp. 2,00
24 Death Secondary Endp. 0,00
24 MI Secondary Endp. 2,00
24 TVR Secondary Endp. 0,00
24 *Death, MI, TVR Composite and primary endp. 9,00
24 Death Secondary Endp. 0,00
24 MI Secondary Endp. 3,00
24 TVR Secondary Endp. 6,00
24 *Death, MI, TVR Composite and primary endp. 10,00 1,07
24 Death Secondary Endp. 10,00
24 MI Secondary Endp. 1,00
24 TVR Secondary Endp. 3,00
24 PCI Secondary Endp. 7,00
24 CABG Secondary Endp. 2,00
24 Bolus only Secondary Endp. 1,07
24 Bolus+infusion Secondary Endp. 1,1
24 Diabetes Secondary Endp. 1
24 Unstable angina Secondary Endp. 1,07
24 TnT> 0,03 microg/L Secondary Endp. 1,15
25 *Access site complication, Death, Major bleeding, 
MI, Rehospitalization, Severe thrombocytopenia, 
TVR Composite and primary endp. 11,10
25 *Death, MI, TVR Composite and secondary endp. 8,70 0,97
25 Death Secondary Endp. 0,60
25 MI Secondary Endp. 2,40
25 TVR Secondary Endp. 6,50
26 *Cardiac death, MI, TLR Composite and primary endp. 25,80 0,52
26 Death Secondary Endp. 10,80 0,75
26 Cardiac death Secondary Endp. 7,50 0,83
26 MI Secondary Endp. 6,50 0,28
26 MI (Q-wave) Secondary Endp. 2,20 0,17
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26 MI (Non-Q-wave) Secondary Endp. 4,30 0,43
26 TLR Secondary Endp. 17,20 0,39
26 TLR (Percutaneous) Secondary Endp. 15,10 0,33
26 TLR (Surgical) Secondary Endp. 4,30 0,41
26 TVR Secondary Endp. 18,30 0,48
26 TVR (Percutaneous) Secondary Endp. 16,10 0,41
26 TVR (Surgical) Secondary Endp. 4,30 0,41
26 ST Secondary Endp. 3,20 0,27
26 Target vessel failure Secondary Endp. 26,90 0,57
26 *Death, MI, ST Composite and secondary endp. 17,20 0,52
26 *Cardiac death, MI, TLR Composite and primary endp. 15,10 0,65
26 Death Secondary Endp. 4,10 0,98
26 Cardiac death Secondary Endp. 2,60 0,57
26 MI Secondary Endp. 4,30 0,93
26 MI (Q-wave) Secondary Endp. 1,20 1,69
26 MI (Non-Q-wave) Secondary Endp. 3,10 0,64
26 TLR Secondary Endp. 12,00 0,64
26 TLR (Percutaneous) Secondary Endp. 10,60 0,68
26 TLR (Surgical) Secondary Endp. 2,40 0,31
26 TVR Secondary Endp. 13,70 0,67
26 TVR (Percutaneous) Secondary Endp. 12,30 0,7
26 TVR (Surgical) Secondary Endp. 2,40 0,31
26 ST Secondary Endp. 2,60 1,06
26 Target vessel failure Secondary Endp. 16,80 0,64
26 *Death, MI, ST Composite and secondary endp. 7,90 1,06
27 *Death, MI, TVR Composite and primary endp. 17,20 0,77
27 Death Secondary Endp. 8,40 0,92
27 MI Secondary Endp. 5,50 0,81
27 *Death, MI Composite and secondary endp. 12,80 0,83
27 TVR Secondary Endp. 7,50 0,55
27 ST Secondary Endp. 2,70 0,4
27 *Death, MI, TVR Composite and primary endp. 25,70 0,74
27 Death Secondary Endp. 13,70 0,8
27 MI Secondary Endp. 6,90 1,01
27 *Death, MI Composite and secondary endp. 19,10 0,82
27 TVR Secondary Endp. 11,30 0,57
27 ST Secondary Endp. 3,90 0,47
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# CASE 3. 
 
with(Statistics); 
 
b10 := 'b10'; beta1 := 'beta1'; b20 := 'b20'; beta2 := 'beta2'; p2 := 'p2'; theta := 'theta'; 
 
listbeta1s := [1]; 
listbeta2s := [1]; 
listthetas := [.909887477, 1.547230858, 2.236162306, 3.010694328, 3.92618959, 5.086432004, 6.725813222]; 
listps := [[0.35e-1, .1], [0.35e-1, .15], [0.35e-1, .2], [0.5e-1, .1], [0.5e-1, .15], [0.5e-1, .2], [0.9e-1, .1], [0.9e-1, .15], [0.9e-1, .2], [.125, 
.1], [.125, .15], [.125, .2]]; 
listRR := [[.5, [.4, .5, .6, .7, .8, .9]], [.6, [.4, .5, .6, .7, .8, .9]], [.7, [.4, .5, .6, .7, .8, .9]], [.8, [.4, .5, .6, .7, .8, .9]]]; 
OutFile := "CASE3Scenarios"; 
 
Escenari:=1: 
b10 := 1/(-log(1-p1))^(1/beta1): 
VL := proc (b20) options operator, arrow; exp(-1/b20^beta2) end proc: 
UL := proc (v,b20) options operator, arrow; exp((b20*(-log(v))^(1/beta2))^beta1*log(1-p1)) end proc: 
#g was named before fstar 
g := proc (u, v) options operator, arrow; (1-exp(-theta))*theta*exp(-theta*(u+v))/(exp(-theta)+exp(-theta*(u+v))-exp(-theta*u)-exp(-
theta*v))^2 end proc: 
f := proc(x) options operator, arrow; evalf(value(int(Int(g(u, v), u = 0 .. UL(v,x)), v = VL(x) .. 1))) end proc: 
 
for beta1 in listbeta1s do 
  for beta2 in listbeta2s do 
      for probs in listps do 
        p2:=probs[2]: 
        p1:=probs[1]: 
        listB20s:=[]: 
        for theta in listthetas do 
        g0:=0.5: g1:=10.0: 
        v0:=f(g0): 
        v1:=f(g1):vn:=v1: 
        while (v1<p2 and v0>p2 and abs(g1-g0)>0.0001 and abs(vn-p2)>0.00001) do 
          gn:=g0-(v0-p2)*(g0-g1)/(v0-v1): 
          vn:=f(gn): 
          if(vn<=p2) then g1:=gn: v1:=vn else g0:=gn: v0:=vn: end if: 
        end do: 
        listB20s:=[op(listB20s),[theta,gn]] 
      end do: 
 
# Got one list of Thetas/B20s... 
      for descRRs in listRR do 
        printf("%4d%c",Escenari,10); 
        fprintf(OutFile,"%4d,%5.3f,%5.3f,%3.4f,[%3.4f",Escenari,beta1,beta2,descRRs[1],descRRs[2][1]); 
        for RR2 in descRRs[2][2..] do 
          fprintf(OutFile,",%3.4f",RR2): 
        end do: 
        fprintf(OutFile,"],%3.4f,%3.4f,[[%12.8f,%12.8f]",p1,p2,listB20s[1][1], listB20s[1][2]): 
        for pair in listB20s[2..] do 
          fprintf(OutFile,",[%12.8f,%12.8f]",pair[1],pair[2]): 
        end do: 
        fprintf(OutFile,"]%c",010); Escenari:=Escenari+1: 
      end do: 
    end do: 
  end do: 
end do: 
 
 
fclose(OutFile); 
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 # ARE T* v T. CASE3 
 
LOAD THE FOLLOWING: 
with(Statistics); 
with(plots); 
with(ExcelTools); 
with(StringTools); 
 
COLOR FOR PLOTS, VALUES FOR RHO 
 
colors := [red, green, blue, magenta, brown, orange]; i := 1; PLOTS := []; 
assume(t > 0, t < 1, x > 0); 
ValsRho := [seq(i, i = .15 .. .75, .1)]; 
 
 
ValsTheta:=[ ]:theta:='theta':numRhos:=0: 
for rho in ValsRho do 
  numRhos:=numRhos+1: 
  auxtheta:=fsolve(1-12*(Int((theta*t-2*t^2)/((exp(t)-1)*theta), t = 0 .. theta))/theta^2 = rho, theta); 
  ValsTheta:=[op(ValsTheta),auxtheta]: 
end do: 
print("ValsTheta := "): ValsTheta; 
 
 
Tabulation of ARE for different parameters: 
ScenariosFile := "C:/Users/Moi/Desktop/SOLVER/CASE3Scenarios.dat"; 
//This is the file that describes the desired scenaries 
 
PrimeraLinea := 1; 
 
FitxerExcel := "C:/Users/Moi/Desktop/SOLVER/Case3.xls"; 
 
Define procedures: 
 
# Pressing this button (re)defines the computation procedures 
 
 
toStr := proc (v) options operator, arrow; sprintf("%7.4f", v) end proc: 
 
capcaleres := proc () options operator, arrow; 
    global PrimeraLinea;FitxerExcel; 
    Export(Vector[row](["Scenario", "Beta_1", "Beta_2", "p_1", "p_2", "RR_1", "Rho", "b20", "RR_2","ARE", 
"RR_2","ARE","RR_2","ARE","RR_2","ARE","RR_2","ARE", "RR_2","ARE"]),FitxerExcel,1,cat("A",PrimeraLinea)): 
    PrimeraLinea:=PrimeraLinea+1; 
end proc: 
 
doOne:= proc (beta1,beta2,RR1,RR2,p1,p2,b20s) 
global AREs,ARETTstar, ARETstarT; 
local 
v,nl,b11,b21,b10,b20,theta,T10,fT10,FT10,ST10,T11,fT11,FT11,ST11,T20,fT20,FT20,ST20,T21,fT21,FT21,ST21,C0,C1,AUX,fstar
0,fstar1,numlin,Sstar0,Lstar0,Sstar1,Lstar1,HRstar,logHRstar,tmp3,tmp4; 
description "fills up AREs with the ARETstarT values for the ValsTheta for these params"; 
    nl := 10:numlin:=0:AREs:=[]: 
    b10 := 1/(-log(1-p1))^(1/beta1): 
    b11 := b10/RR1^(1/beta1): 
  for v in b20s do 
  theta:=v[1]: b20:=v[2]: 
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 b21:=b20/RR2^(1/beta2): 
        T10 := RandomVariable(Weibull(b10, beta1)): 
        fT10:=(t)->PDF(T10,t): FT10:=(t)->CDF(T10,t): ST10:=(t)->1-FT10(t): 
        T11 := RandomVariable(Weibull(b11, beta1)): 
        fT11:=(t)->PDF(T11,t): FT11:=(t)->CDF(T11,t): ST11:=(t)->1-FT11(t): 
        T20 := RandomVariable(Weibull(b20, beta2)): 
        fT20:=(x)->PDF(T20,x): FT20:=(x)->CDF(T20,x): ST20:=(t)->1-FT20(t): 
        T21 := RandomVariable(Weibull(b21, beta2)): 
        fT21:=(x)->PDF(T21,x): FT21:=(x)->CDF(T21,x): ST21:=(t)->1-FT21(t): 
        C0 := proc (t, x) options operator, arrow; -log(1+(exp(-theta*ST10(t))-1)*(exp(-theta*ST20(x))-1)/(exp(-theta)-1))/theta end 
proc: 
        AUX:=simplify((exp(-theta*ST10(t))*(exp(-theta*ST20(t))-1)*fT10(t)+exp(-theta*ST20(t))*(exp(-theta*ST10(t))-
1)*fT20(t))/(exp(-theta*C0(t, t))*(exp(-theta)-1)), exp): 
        fstar0 := unapply(AUX, t): 
        Sstar0 := proc (t) options operator, arrow; C0(t, t) end proc: 
        Lstar0 := proc (t) options operator, arrow; simplify(fstar0(t)/Sstar0(t),exp) end proc: 
        C1 := proc (t, x) options operator, arrow; -log(1+(exp(-theta*ST11(t))-1)*(exp(-theta*ST21(x))-1)/(exp(-theta)-1))/theta end 
proc: 
        AUX:=simplify((exp(-theta*ST11(t))*(exp(-theta*ST21(t))-1)*fT11(t)+exp(-theta*ST21(t))*(exp(-theta*ST11(t))-
1)*fT21(t))/(exp(-theta*C1(t, t))*(exp(-theta)-1)), exp): 
        fstar1 := unapply(AUX,t): 
        Sstar1 := proc (t) options operator, arrow; C1(t, t) end proc: 
        Lstar1 := proc (t) options operator, arrow; evalf(fstar1(t)/Sstar1(t)) end proc: 
        HRstar := proc (t) options operator, arrow; evalf(Lstar1(t)/Lstar0(t)) end proc: 
        logHRstar := proc (t) options operator, arrow; evalf(log(Lstar1(t)/Lstar0(t))) end proc: 
 
 
        tmp3 := proc (t) options operator, arrow; evalf(logHRstar(t)*fstar0(t)) end proc: 
        tmp4 := evalf(Int(tmp3(t), t = 0. .. 1, method = _d01ajc)): 
        #ARETTstar := log(RR1)^2*FT10(1)*(1-Sstar0(1))/tmp4^2: 
        #ARETstarT:=evalf(1/ARETTstar): 
        ARETstarT:=evalf(tmp4^2/(log(RR1)^2*FT10(1)*(1-Sstar0(1)))): 
        AREs := [ op(AREs),evalf(ARETstarT)]: 
    end do: 
end proc: 
 
doPlot:=proc(line) 
description "parses line and produces plot defined within"; 
global scen,beta1,beta2,RR1,RR2,ValsLambda2,p1,p2,PLOTS,extrem,lbl,fitx,capt,AREs; 
local i, b20s; 
# vars for Excel export: 
global ScenStart, PrimeraLinea, NxtCol, AREsStr, ExcelCol; 
 
    if line=0 then return: end if: 
    scen,beta1,beta2,RR1,ValsLambda2,p1,p2,b20s:=parse(line): 
 
    # Export common parameters of this scenario to excel file: 
    ScenStart:=PrimeraLinea: PrimeraLinea:=PrimeraLinea+nops(ValsRho): 
    for i from ScenStart to PrimeraLinea-1 do 
     Export(Vector[row]([scen,beta1,beta2,p1,p2,RR1]),FitxerExcel,1,"A"||i): 
    od: 
    Export(Vector(map(toStr,ValsRho)),FitxerExcel,1,"G"||ScenStart): 
    Export(Vector(map(proc (i) options operator, arrow; b20s[i][2] end proc, [seq(j, j = 1 .. 7)])), FitxerExcel,1,"H"||ScenStart): 
    NxtCol:="I": 
    # End common parameters export 
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 PLOTS := []: i := 1: 
    for RR2 in ValsLambda2 do 
        doOne(beta1,beta2,RR1,RR2,p1,p2,b20s): 
        PLOTS := [op(PLOTS), plot(ValsRho, AREs, color = colors[i], thickness=4)]: 
       # for extrem from numRhos by -1 to 1 while evalf(AREs[numRhos])>5 do; end do: 
       # if extrem > 1 then 
       extrem:=nops(ValsRho): 
            lbl := textplot([ValsRho[extrem]+0.05, min(4.8,AREs[extrem]), typeset(RR_2 = RR2), color = colors[i]]): 
            PLOTS:=[op(PLOTS), lbl]: 
      #  end if: 
        i:=i+1: 
        # Export a column of AREs for this RR2 to excel file: 
        AREsStr:=map(toStr, AREs); 
        #ExcelCol:=map(proc (i) options operator, arrow; 
         #                 cat(toStr(RR2), ",", toStr(AREs[i])) end proc, 
        #              [seq(i, i = 1 .. nops(AREs))]): 
        ExcelCol:=map(proc(i) options operator, arrow; 
         toStr(RR2) end proc, [seq(i, i=1..nops(AREs))]): 
        Export(Vector(ExcelCol),FitxerExcel,1,cat(NxtCol,ScenStart)): 
        NxtCol:=Char(Ord(NxtCol)+1): 
        Export(Vector(AREsStr),FitxerExcel,1,cat(NxtCol,ScenStart)): 
        NxtCol:=Char(Ord(NxtCol)+1): 
        # END Export a column... 
 
    end do: 
    fitx:=sprintf("C:/Users/Moi/Desktop/SOLVER/Scenario_%03d",scen): 
    plotsetup(png, plotoutput = fitx, plotoptions = "width=1000,height=1000,orientation=portrait"); 
    display(PLOTS, axis[2] = [gridlines = [1], mode = log, tickmarks = [.25, .5, 1, 2, 4]], labels = [typeset('rho'), "evalf(ARETstarT)"], 
labeldirections = [horizontal, vertical], view = [0 .. .85, .2 .. 5],caption=typeset(shape_1=beta1,"  ",shape_2=beta2,"  ",RR_1=RR1,"  
",ProbUnc_T1=p1,"  ",ProbUnc_T2=p2)); 
    #print(fitx," done."); 
end proc: 
 
capcaleres(): 
 
fclose(ScenariosFile); 
for i to 48 do doPlot(readline(ScenariosFile)); fitx end do; 
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Appendix D
ARE Plots
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